

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspal642cxy

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 APR 08 BEILSTEIN: Reload and Implementation of a New Subject Area  
NEWS 4 APR 09 ZDB will be removed from STN  
NEWS 5 APR 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB  
NEWS 6 APR 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS  
NEWS 7 APR 22 BIOSIS Gene Names now available in TOXCENTER  
NEWS 8 APR 22 Federal Research in Progress (FEDRIP) now available  
NEWS 9 JUN 03 New e-mail delivery for search results now available  
NEWS 10 MEDLINE Reload  
NEWS 11 JUN 10 PCTFULL has been reloaded  
NEWS 12 JUL 02 FORCE no longer contains STANDARDS file segment  
NEWS 13 JUL 22 USAN to be reloaded July 26, 2002;  
saved answer sets no longer valid  
NEWS 14 JUL 29 Enhanced polymer searching in REGISTRY  
NEWS 15 JUL 30 NETFIRST to be removed from STN  
NEWS 16 AUG 08 CANCERLIT Reload  
NEWS 17 AUG 08 PHARMAMarkLetter(PHARMAML) - new on STN  
NEWS 18 AUG 08 NTIS has been reloaded and enhanced  
NEWS 19 AUG 19 Aquatic Toxicity Information Retrieval (AQUIRE)  
now available on STN  
NEWS 20 AUG 19 IFIPAT, IFICDB, and IFIUDB have been reloaded  
NEWS 21 AUG 19 The MEDLINE file segment of TOXCENTER has been reloaded  
NEWS 22 AUG 26 Sequence searching in REGISTRY enhanced  
NEWS 23 SEP 03 JAPIO has been reloaded and enhanced  
NEWS 24 SEP 16 Experimental properties added to the REGISTRY file  
NEWS 25 SEP 16 Indexing added to some pre-1967 records in CA/CAPLUS  
NEWS 26 SEP 16 CA Section Thesaurus available in CAPLUS and CA  
NEWS 27 OCT 01 CASREACT Enriched with Reactions from 1907 to 1985

NEWS EXPRESS  
October 14 CURRENT WINDOWS VERSION IS V6.01.  
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP).  
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002  
STN Operating Hours Plus Help Desk Availability  
NEWS HOURS  
General Internet Information  
NEWS LOGIN  
Welcome Banner and News Items  
NEWS PHONE  
Direct Dial and Telecommunication Network Access to STN  
NEWS WWW  
CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 15:43:14 ON 17 OCT 2002

=> file medline, cancerlit, biosis, confsci, caplus, uspatfull  
COST IN U.S. DOLLARS  
ENTRY  
TOTAL  
0.21  
SESSION  
0.21

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 15:43:55 ON 17 OCT 2002

FILE 'CANCERLIT' ENTERED AT 15:43:55 ON 17 OCT 2002

FILE 'BIOSIS' ENTERED AT 15:43:55 ON 17 OCT 2002  
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'CONFSCI' ENTERED AT 15:43:55 ON 17 OCT 2002  
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'CAPLUS' ENTERED AT 15:43:55 ON 17 OCT 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGTERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 15:43:55 ON 17 OCT 2002  
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> s hsp or heat (a) shock (a) protein  
L1 4 FILES SEARCHED...  
61040 HSP OR HEAT (A) SHOCK (A) PROTEIN

=> s l1 and peptide (3a) associat?  
L2 554 L1 AND PEPTIDE (3A) ASSOCIAT?  
L3 10567 L2 AND RELEASE? OR DISASSOCIAT?

=> s l2 and releas? or disassociat?  
L3 10567 L2 AND RELEASE? OR DISASSOCIAT?  
=> d his  
(FILE 'HOME' ENTERED AT 15:43:14 ON 17 OCT 2002)

FILE 'MEDLINE, CANCERLIT, BIOSIS, CONFSCI, CAPLUS, USPATFULL' ENTERED AT  
15:43:55 ON 17 OCT 2002

L1 61040 S HSP OR HEAT (A) SHOCK (A) PROTEIN  
L2 554 S L1 AND PEPTIDE (3A) ASSOCIAT?  
L3 10567 S L2 AND RELEASE? OR DISASSOCIAT?

=> s l2 and low (a) ph  
L4 54 L2 AND LOW (A) PH

=> dup rem l4  
PROCESSING COMPLETED FOR L4

L5 54 DUP REM L4 (0 DUPLICATES REMOVED)

=> s l5 not py=>1994  
'1994' NOT A VALID FIELD CODE  
L6 0 L5 NOT PY=>1994

=> d l-54

L6 HAS NO ANSWERS  
'1-54' IS NOT A VALID SEARCH STATUS KEYWORD  
Search status keywords:  
NONE --- Display only the number of postings.  
STATUS -- Display statistics of the search.

ENTER SEARCH STATUS OPTION (NONE), STATUS, OR ? :end

=> d his

(FILE 'HOME' ENTERED AT 15:43:14 ON 17 OCT 2002)

FILE 'MEDLINE, CANCERLIT, BIOSIS, CONFSCI, CAPLUS, USPATFULL' ENTERED AT

15:43:55 ON 17 OCT 2002

L1 61040 S HSP OR HEAT (A) SHOCK (A) PROTEIN  
L2 554 S L1 AND PEPTIDE (3A) ASSOCIAT?  
L3 10567 S L2 AND RELEAS? OR DISASSOCIAT?  
L4 54 S L2 AND LOW (A) PH  
L5 54 DUP REM L4 (0 DUPLICATES REMOVED)  
L6 0 S L5 NOT PY->1994

=> d 15 1-54

L5 ANSWER 1 OF 54 USPATFULL  
AN 2002:259392 USPATFULL  
TI Single-chain polypeptides  
IN Nissen, Torben Lauesgaard, Frederiksberg C, DENMARK  
PI US 2002142964 A1 20021003  
AI US 2001-3496 A1 20011101 (10)  
PRAI US 2000-245727P 20001102 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3866  
INCL INCLM: 514/012.000  
INCLS: 530/399.000  
NCL NCLM: 514/012.000  
NCLS: 530/399.000  
IC [7]  
ICM: A61K038-22  
ICS: C07K014-575

L5 ANSWER 2 OF 54 USPATFULL  
AN 2002:251138 USPATFULL  
TI Methods of diagnosis and treatment of osteoporosis  
IN Lewandowski, Kai-Uwe, Brookline, MA, UNITED STATES  
PI Trantolo, Debra J., Princeton, MA, UNITED STATES  
AI US 2002137082 A1 20020926  
US 2002-54171 A1 20020117 (10)  
PRAI US 2001-263109P 20010119 (60)  
US 2001-304887P 20010712 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1719  
INCL INCLM: 435/006.000  
INCLS: 435/007.210  
NCL NCLM: 435/006.000  
NCLS: 435/007.210  
IC [7]  
ICM: C12Q001-68  
ICS: G01N033-567

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 54 USPATFULL  
AN 2002:191567 USPATFULL  
TI Pharmaceutical or food composition for treating pathologies associated  
IN with graft rejection or an allergic or autoimmune reaction  
Henot, Frederic, Brussels, BELGIUM  
Legon, Thierry, Korbeek Lo, BELGIUM  
Duchateau, Jean, Soignies, BELGIUM  
Servais, Genevieve, Soignies, BELGIUM

PI US 2002102632 A1 20020801  
AI US 2001-891148 A1 20010625 (9)  
RLI Continuation-in-part of Ser. No. US 1999-380548, filed on 28 Oct 1999,  
PATENTED  
PRAI 88 1997-199 19970305  
DT Utility  
FS APPLICATION  
LN.CNT 1426  
INCL INCLM: 435/068.100  
INCLS: 424/185.100  
NCL NCLM: 435/068.100  
NCLS: 424/185.100  
IC [7]  
ICM: C12P021-06  
ICS: A61K039-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 54 USPATFULL  
AN 2002:164658 USPATFULL  
TI Immunotherapeutic methods for extracorporeal modulation of CD36 and its  
ligands  
IN Srivastava, Pramod K., Avon, CT, UNITED STATES  
PI US 2002086276 A1 20020704  
AI US 2000-750973 A1 20001228 (9)  
DT Utility  
FS APPLICATION  
LN.CNT 1813  
INCL INCLM: 435/002.000  
INCLS: 424/140.100  
NCL NCLM: 435/002.000  
NCLS: 424/140.100  
IC [7]  
ICM: A61K039-395

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 54 USPATFULL  
AN 2002:119336 USPATFULL  
TI Immunotherapeutic stress protein-peptide complexes against cancer  
IN Srivastava, Pramod K., Avon, CT, UNITED STATES  
PA Mount Sinai School of Medicine of New York University (U.S. corporation)  
PI US 2002061316 A1 20020523  
AI US 2001-992613 A1 20011114 (9)  
RLI Continuation of Ser. No. US 2000-489218, filed on 21 Jan 2000, PENDING  
Continuation of Ser. No. US 1998-61365, filed on 16 Apr 1998, PATENTED  
Division of Ser. No. US 1994-315892, filed on 30 Sep 1994, PATENTED  
DT Utility  
FS APPLICATION  
LN.CNT 811  
INCL INCLM: 424/277.100  
INCLS: 424/185.100  
NCL NCLM: 424/277.100  
NCLS: 424/185.100  
IC [7]  
ICM: A61K039-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 54 USPATFULL  
AN 2002:119332 USPATFULL  
TI Innate immune system-directed vaccines  
IN Medzhitov, Ruslan, New Haven, CT, UNITED STATES  
PI US 2002061312 A1 20020523  
AI US 2001-752832 A1 20010103 (9)  
PRAI US 2000-222042P 20000731 (60)  
DT Utility  
FS APPLICATION

LN.CNT 2414  
INCL INCLM: 424/192.100  
INCLS: 435/069.600; 435/325.000; 530/350.000; 536/023.400  
NCL NCLM: 424/192.100  
NCLS: 435/069.600; 435/325.000; 530/350.000; 536/023.400  
IC [7]  
ICM: A61K039-35  
ICS: C12N005-10  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 54 USPTAFULL  
AN 2002:112868 USPTAFULL  
TI COMPOSITIONS AND METHODS USING COMPLEXES OF CALRETICULIN AND ANTIGENIC MOLECULES  
IN GILBOA, ELI, DURHAM, NC, UNITED STATES  
NAYR, SMITA K., DURHAM, NC, UNITED STATES  
NICHILITTA, CHRISTOPHER V., DURHAM, NC, UNITED STATES  
PI US 2002058609 A1 20020516  
AI US 1999-261473 A1 19990226 (9)  
DT Utility  
FS APPLICATION  
LN.CNT 2415  
INCL INCLM: 514/002.000  
INCLS: 530/300.000; 530/350.000  
NCL NCLM: 514/002.000  
NCLS: 530/300.000; 530/350.000  
IC [7]  
ICM: A01N037-18  
ICS: A61K038-00; A61K039-00; C07K002-00; C07K004-00; C07K005-00; C07K007-00; C07K014-00; C07K016-00; C07K017-00; C07K001-00  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 54 USPTAFULL  
AN 2002:66639 USPTAFULL  
TI Compositions comprising **heat shock proteins** or alpha(2) macroglobulin, antigenic molecules and saponins, and methods of use thereof  
IN Armen, Garo H., Manhasset, NY, UNITED STATES  
PI US 2002037290 A1 20020328  
AI US 2001-909778 A1 20010720 (9)  
PRAI US 2000-223133P 20000807 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 4136  
INCL INCLM: 424/178.100  
INCLS: 514/012.000; 514/026.000  
NCL NCLM: 424/178.100  
NCLS: 514/012.000; 514/026.000  
IC [7]  
ICM: A61K039-395  
ICS: A61K038-17  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 9 OF 54 USPTAFULL  
AN 2002:48016 USPTAFULL  
TI Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy  
IN Srivastava, Pramod K., Avon, CT, UNITED STATES  
PI US 2002028207 A1 20020307  
AI US 2001-873403 A1 20010604 (9)  
RLI Continuation-in-part of Ser. No. US 2000-625139, filed on 25 Jul 2000, PENDING  
PRAI US 2000-209266P 20000602 (60)  
DT Utility  
FS APPLICATION

LN.CNT 4477  
INCL INCLM: 424/185.100  
INCLS: 424/190.100; 424/178.100; 530/391.100  
NCL NCLM: 424/185.100  
NCLS: 424/190.100; 424/178.100; 530/391.100  
IC [7]  
ICM: A61K039-40  
ICS: A61K039-395; C07K016-46  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 10 OF 54 USPTAFULL  
AN 2002:262059 USPTAFULL  
TI Therapeutic and prophylactic methods using **heat shock proteins**  
IN Srivastava, Pramod K., Riverdale, NY, United States  
PA Fordham University, Bronx, NY, United States (U.S. corporation)  
PI US 8461615 B1 20021008  
AI US 2000-545351 20000407 (9)  
RLI Continuation of Ser. No. US 1999-372022, filed on 9 Aug 1999 Division of Ser. No. US 1995-527547, filed on 13 Sep 1995, now patented, Pat. No. US 5935576  
DT Utility  
FS GRANTED  
LN.CNT 1684  
INCL INCLM: 424/193.100  
INCLS: 424/194.100; 424/184.100; 424/196.110; 424/197.110; 424/204.100; 424/195.110; 530/324.000; 514/002.000; 514/012.000; 514/021.000  
NCL NCLM: 424/193.100  
NCLS: 424/194.100; 424/184.100; 424/196.110; 424/197.110; 424/204.100; 424/195.110; 530/324.000; 514/002.000; 514/012.000; 514/021.000  
IC [7]  
ICM: A61K039-385  
ICS: A61K038-02; A61K038-16; A61K038-17; C07K007-00  
424/193.1; 424/194.1; 424/184.1; 424/196.11; 424/197.11; 424/204.1; 530/324; 514/2; 514/12; 514/21

L5 ANSWER 11 OF 54 USPTAFULL  
AN 2002:246727 USPTAFULL  
TI Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens  
IN Srivastava, Pramod K., Riverdale, NY, United States  
PA Mount Sinai School of Medicine of New York University, New York, NY, United States (U.S. corporation)  
PI US 6455503 B1 20020924  
AI US 1999-412420 19991005 (9)  
RLI Continuation of Ser. No. US 704727, now patented, Pat. No. US 6048530 Continuation-in-part of Ser. No. US 1994-210421, filed on 16 Mar 1994, now patented, Pat. No. US 5961979, issued on 5 Oct 1999  
DT Utility  
FS GRANTED  
LN.CNT 1847  
INCL INCLM: 514/021.000  
INCLS: 424/193.100; 424/002.000; 530/344.000; 530/806.000; 530/403.000; 530/300.000; 530/350.000; 514/002.000; 514/012.000; 436/823.000  
NCL NCLM: 514/021.000  
NCLS: 424/193.100; 424/002.000; 530/344.000; 530/806.000; 530/403.000; 530/300.000; 530/350.000; 514/002.000; 514/012.000; 436/823.000  
IC [7]  
ICM: A61K038-00  
ICS: C07K001-00; C07K001-14; C07K002-00; C07K004-12  
424/193.1; 530/300; 530/350; 530/344; 530/806; 530/403; 514/2; 514/12; 514/21; 436/823  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 12 OF 54 USPTAFULL

AN 2002:246373 USPATFULL  
TI Prevention of primary and metastatic neoplastic diseases with  
hsp70-peptide complexes  
IN Srivastava, Pramod K., Riverdale, NY, United States  
Chandawarkar, Rajiv Y., Mineola, NY, United States  
PA Fordham University, Bronx, NY, United States (U.S. corporation)  
PI US 6455048 B1 20020924  
AI US 1999-440173 B1 19991115 (9)  
RLI Division of Ser. No. US 1997-796319, filed on 7 Feb 1997, now patented,  
Pat. No. US 6017540  
DT Utility  
FS GRANTED  
LN.CNT 2334  
INCL INCLM: 424/193.100  
INCLS: 424/277.100; 424/093.100; 424/093.700; 424/093.710; 530/403.000;  
530/417.000; 514/002.000; 514/012.000; 435/069.100; 435/070.100;  
436/543.000  
NCL NCLM: 424/193.100  
NCLS: 424/277.100; 424/093.100; 424/093.700; 424/093.710; 530/403.000;  
530/417.000; 514/002.000; 514/012.000; 435/069.100; 435/070.100;  
436/543.000  
IC [7]  
ICM: A61K039-385  
ICS: A61K039-38; A61K038-16; A61K038-17; C07K007-00  
424/277.1; 424/193.1; 424/93.1; 424/93.7; 424/93.71; 435/69.1; 435/70.1;  
436/543; 530/403; 530/417; 514/2; 514/12  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L5 ANSWER 13 OF 54 USPATFULL  
AN 2002:238649 USPATFULL  
TI Methods for generating antigen-reactive T cells in vitro  
IN Srivastava, Pramod K., Avon, CT, United States  
PA University of Connecticut Health Center, Farmington, CT, United States  
(U.S. corporation)  
PI US 6451316 B1 20020917  
AI US 1998-166401 19981005 (9)  
DT Utility  
FS GRANTED  
LN.CNT 2357  
INCL INCLM: 424/193.100  
INCLS: 435/007.200; 435/007.210; 435/007.240; 435/325.000; 435/354.000;  
435/366.000; 435/355.000; 435/372.300; 435/373.000; 435/384.000;  
530/350.000  
NCL NCLM: 424/193.100  
NCLS: 435/007.200; 435/007.210; 435/007.240; 435/325.000; 435/354.000;  
435/366.000; 435/355.000; 435/372.300; 435/373.000; 435/384.000;  
530/350.000  
IC [7]  
ICM: G01N033-53  
ICS: G01N033-567; C12N005-06; C12N005-08; A61K039-385  
530/350; 424/193.1; 435/7.2; 435/7.21; 435/7.24; 435/325; 435/354;  
435/355; 435/366; 435/372.3; 435/373; 435/384  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L5 ANSWER 14 OF 54 USPATFULL  
AN 2002:230611 USPATFULL  
TI Therapeutic and prophylactic methods using heat shock  
proteins  
IN Srivastava, Pramod K., Riverdale, NY, United States  
PA Fordham University, Bronx, NY, United States (U.S. corporation)  
PI US 6447781 B1 20020910  
AI US 2000-545352 20000407 (9)  
RLI Continuation of Ser. No. US 1999-372022, filed on 9 Aug 1999 Division of  
Ser. No. US 1995-527547, filed on 13 Sep 1995, now patented, Pat. No. US  
5935576

DT Utility  
FS GRANTED  
LN.CNT 1671  
INCL INCLM: 424/193.100  
INCLS: 424/194.100; 424/184.100; 424/277.100; 530/324.000; 514/002.000;  
NCL NCLM: 424/193.100  
NCLS: 424/194.100; 424/184.100; 424/277.100; 530/324.000; 514/002.000;  
514/012.000  
IC [7]  
ICM: A61K039-385  
ICS: A61K038-02; A61K038-16; A61K038-17; C07K007-00  
424/193.1; 424/277.1; 424/194.1; 530/324; 514/2; 514/12  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L5 ANSWER 15 OF 54 USPATFULL  
AN 2002:230610 USPATFULL  
TI Prevention of primary and metastatic neoplastic diseases with  
hsp90-peptide complexes  
IN Srivastava, Pramod K., Riverdale, NY, United States  
Chandawarkar, Rajiv Y., Mineola, NY, United States  
PA Fordham University, Bronx, NY, United States (U.S. corporation)  
PI US 6447780 B1 20020910  
AI US 1999-427432 19991026 (9)  
RLI Division of Ser. No. US 1997-796319, filed on 7 Feb 1997, now patented,  
Pat. No. US 6017540  
DT Utility  
FS GRANTED  
LN.CNT 2338  
INCL INCLM: 424/193.100  
INCLS: 424/093.100; 424/277.100; 424/184.100; 530/324.000; 530/403.000;  
530/417.000; 514/002.000; 514/012.000  
NCL NCLM: 424/193.100  
NCLS: 424/093.100; 424/277.100; 424/184.100; 530/324.000; 530/403.000;  
530/417.000; 514/002.000; 514/012.000  
IC [7]  
ICM: A61K039-385  
ICS: A61K039-38; A61K038-16; A61K038-17; C07K007-00  
424/193.1; 424/93.1; 424/277.1; 424/184.1; 530/324; 530/403; 530/417;  
514/2; 514/12  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L5 ANSWER 16 OF 54 USPATFULL  
AN 2002:209116 USPATFULL  
TI Prevention of primary and metastatic neoplastic diseases with  
GP96-peptide complexes  
IN Srivastava, Pramod K., Riverdale, NY, United States  
Chandawarkar, Rajiv Y., Mineola, NY, United States  
PA Fordham University, Bronx, NY, United States (U.S. corporation)  
PI US 6436404 B1 20020820  
AI US 1999-439686 19991115 (9)  
RLI Division of Ser. No. US 1997-796319, filed on 7 Feb 1997, now patented,  
Pat. No. US 6017540  
DT Utility  
FS GRANTED  
LN.CNT 2332  
INCL INCLM: 424/193.100  
INCLS: 424/277.100; 424/093.100; 424/093.700; 424/093.710; 530/403.000;  
530/417.000; 514/002.000; 514/012.000; 435/069.100; 435/070.100;  
436/543.000  
NCL NCLM: 424/193.100  
NCLS: 424/093.100; 424/093.700; 424/093.710; 424/277.100; 435/069.100;  
435/070.100; 436/543.000; 514/012.000; 530/403.000;  
530/417.000  
IC [7]

ICM: A61K039-385  
 ICS: A61K039-38; A61K038-16; A61K038-17; C07K007-00  
 424/277.1; 424/193.1; 424/93.1; 424/93.7; 424/93.71; 435/69.1; 435/70.1;  
 436/543; 530/403; 530/417; 514/2  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 17 OF 54 USPATFULL  
 AN 2002:152212 USPATFULL  
 TI Therapeutic and prophylactic methods using **heat shock proteins**  
 IN Srivastava, Pramod K., Riverdale, NY, United States  
 PA Fordham University, Bronx, NY, United States (U.S. corporation)  
 PI US 6410028 B1 20020625  
 AI US 1999-372022 19990809 (9)  
 RLI Division of Ser. No. US 1995-527547, filed on 13 Sep 1995, now patented,  
 Pat. No. US 5935576  
 DT Utility  
 FS GRANTED  
 LN.CNT 1681  
 INCL INCLM: 424/193.100  
 INCLS: 424/194.100; 424/195.110; 424/196.110; 424/197.110; 424/277.100;  
 424/204.100; 424/234.100; 424/274.100; 514/012.000  
 NCLM: 424/193.100  
 NCL INCLS: 424/194.100; 424/195.110; 424/196.110; 424/197.110; 424/204.100;  
 424/234.100; 424/274.100; 424/277.100; 514/012.000  
 IC [7]  
 ICM: A61K039-385  
 ICS: A61K039-12; A61K039-02; A61K039-00; A61K038-00  
 424/193.1; 424/277.1; 424/194.1; 424/195.11; 424/196.11; 424/197.11;  
 424/204.1; 424/234.1; 424/274.1; 514/12  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 18 OF 54 USPATFULL  
 AN 2002:152211 USPATFULL  
 TI Methods for preparation of vaccines against cancer  
 IN Srivastava, Pramod K., Avon, CT, United States  
 PA Fordham University, Bronx, NY, United States (U.S. corporation)  
 PI US 6410027 B1 20020625  
 AI US 1999-360383 B1 19990723 (9)  
 RLI Division of Ser. No. US 1997-988878, filed on 11 Dec 1997, now patented,  
 Pat. No. US 5948646  
 DT Utility  
 FS GRANTED  
 LN.CNT 2163  
 INCL INCLM: 424/193.100  
 INCLS: 424/184.100; 424/194.100; 424/277.100; 435/069.300; 435/320.100;  
 530/403.000; 530/828.000; 536/023.100; 536/023.400; 514/021.000  
 NCLM: 424/193.100  
 NCL INCLS: 424/184.100; 424/194.100; 424/277.100; 435/069.300; 435/320.100;  
 514/021.000  
 IC [7]  
 ICM: A61K038-00  
 ICS: A61K039-00; A61K035-12; C12N015-09; C12N015-12  
 424/184.1; 424/193.1; 424/194.1; 424/271.1; 435/69.3; 435/320.1;  
 435/325; 530/403; 530/828; 536/23.1; 536/23.4; 536/23.5; 514/21  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 19 OF 54 USPATFULL  
 AN 2002:152210 USPATFULL  
 TI Methods for preparation of vaccines against cancer  
 IN Srivastava, Pramod K., Avon, CT, United States  
 PA Fordham University, Bronx, NY, United States (U.S. corporation)  
 PI US 6410026 B1 20020625  
 AI US 1999-360381 19990723 (9)  
 RLI Division of Ser. No. US 1997-988878, filed on 11 Dec 1997, now patented,  
 Pat. No. US 5948646

Pat. No. US 5948646  
 DT Utility  
 FS GRANTED  
 LN.CNT 2170  
 INCL INCLM: 424/193.100  
 INCLS: 424/184.100; 424/194.100; 424/277.100; 435/069.300; 435/320.100;  
 530/403.000; 530/828.000; 536/023.100; 536/023.400; 536/023.500;  
 514/021.000  
 NCLM: 424/193.100  
 NCL INCLS: 424/184.100; 424/194.100; 435/069.300; 435/320.100;  
 514/021.000; 530/403.000; 530/828.000; 536/023.100; 536/023.400;  
 536/023.500  
 IC [7]  
 ICM: A61K038-00  
 ICS: A61K039-00; A61K035-12; C12N015-09; C12N015-12  
 424/184.1; 424/194.1; 424/193.1; 424/277.1; 435/69.3; 435/320.1;  
 435/325; 530/403; 530/828; 536/23.1; 536/23.4; 536/23.5; 514/21  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 20 OF 54 USPATFULL  
 AN 2002:143946 USPATFULL  
 TI Methods for preparation of vaccines against cancer  
 IN Srivastava, Pramod K., Avon, CT, United States  
 PA Fordham University, Bronx, NY, United States (U.S. corporation)  
 PI US 6405700 B1 20020618  
 AI US 1999-360382 19990723 (9)  
 RLI Division of Ser. No. US 1997-988878, filed on 11 Dec 1997, now patented,  
 Pat. No. US 5948646  
 DT Utility  
 FS GRANTED  
 LN.CNT 2171  
 INCL INCLM: 424/193.100  
 INCLS: 424/184.100; 424/194.100; 424/277.100; 435/069.300; 435/320.100;  
 530/403.000; 530/828.000; 536/023.100; 536/023.400; 536/023.500;  
 514/021.000  
 NCLM: 424/193.100  
 NCL INCLS: 424/184.100; 424/194.100; 424/277.100; 435/069.300; 435/320.100;  
 514/021.000; 530/403.000; 530/828.000; 536/023.100; 536/023.400;  
 536/023.500  
 IC [7]  
 ICM: A61K038-00  
 ICS: A61K039-00; A61K035-12; C12N015-09; C12N015-12  
 424/184.1; 424/194.1; 424/277.1; 435/69.3; 530/403; 530/828; 536/23.1;  
 536/23.4; 536/23.5; 514/21  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 21 OF 54 USPATFULL  
 AN 2002:136570 USPATFULL  
 TI Treatment of primary and metastatic neoplastic diseases with  
 HSP70-peptide complexes  
 IN Srivastava, Pramod K., Riverdale, NY, United States  
 PA Chandawarkar, Rajiv Y., Mineola, NY, United States  
 PI US 6403095 B1 20020611  
 AI US 1999-440178 19991115 (9)  
 RLI Division of Ser. No. US 1997-796319, filed on 7 Feb 1997, now patented,  
 Pat. No. US 6017540  
 DT Utility  
 FS GRANTED  
 LN.CNT 2422  
 INCL INCLM: 424/193.100  
 INCLS: 424/277.100; 424/085.100; 424/085.700; 424/085.400; 424/093.100;  
 424/093.710; 436/543.000; 514/002.000; 435/069.100; 435/070.100  
 NCLM: 424/193.100  
 NCL INCLS: 424/085.100; 424/085.400; 424/085.700; 424/093.100; 424/093.710;

IC 424/277.100; 435/069.100; 435/070.100; 436/543.000; 514/002.000

ICM: A61K039-385

EXF ICS: A61K039-00; A23J001-00; C07K001-00; A01N065-00

424/277.1; 424/193.1; 424/85.1; 424/85.7; 424/85.4; 424/93.1; 424/93.7;

424/93.71; 435/69.1; 435/70.1; 514/2; 530/403; 530/417; 436/543

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 22 OF 54 USPTATFULL

AN 2002:129531 USPTATFULL

TI Methods and compositions for eliciting an immune response with

IN hsp90-peptide complexes

PA Srivastava, Pramod K., Riverdale, NY, United States

PI Chandawarkar, Rajiv Y., Mineola, NY, United States

AI Fordham University, Bronx, NY, United States (U.S. corporation)

US 6399070 B1 20020604

RI Division of Ser. No. US 1997-796319, filed on 7 Feb 1997, now patented,

Pat. No. US 6017540

DT Utility

FS GRANTED

LN.CNT 2422

INCL INCLM: 424/193.100

INCLS: 424/277.100; 424/785.100; 424/085.700; 424/085.400; 424/093.100;

424/093.700; 424/093.710; 424/196.110; 424/197.110; 424/204.100;

424/274.100; 424/265.100; 424/234.100; 514/002.000; 530/403.000;

530/417.000; 435/069.100; 435/070.100; 436/543.000

NCLM: 424/193.100

NCLS: 424/085.100; 424/085.400; 424/085.700; 424/093.100; 424/093.700;

424/093.710; 424/196.110; 424/197.110; 424/204.100; 424/234.100;

424/265.100; 424/274.100; 424/277.100; 435/069.100; 435/070.100;

436/543.000; 514/002.000; 530/403.000; 530/417.000

IC ICM: A61K039-385

EXF ICS: A61K039-00; A61K039-02; A61K039-002; A01N037-18; A01N065-00

424/277.1; 424/193.1; 424/85.1; 424/85.4; 424/193.1; 424/93.1; 424/93.7;

424/93.71; 424/274.1; 424/265.1; 424/196.11; 424/197.11; 424/204.1;

424/234.1; 435/69.1; 435/70.1; 436/543; 514/2; 530/403; 530/417

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 23 OF 54 USPTATFULL

AN 2002:129530 USPTATFULL

TI Prevention of infectious diseases with hsp70-peptide complexes

IN Srivastava, Pramod K., Riverdale, NY, United States

PI Chandawarkar, Rajiv Y., Mineola, NY, United States

PA Fordham University, Bronx, NY, United States (U.S. corporation)

US 6399069 B1 20020604

RI Division of Ser. No. US 1997-796319, filed on 7 Feb 1997, now patented,

Pat. No. US 6017540

DT Utility

FS GRANTED

LN.CNT 2365

INCL INCLM: 424/193.100

INCLS: 424/093.700; 424/093.710; 424/196.110; 424/197.110; 424/204.100;

424/234.100; 424/265.100; 424/274.100; 435/069.100; 435/070.100;

435/325.000; 436/543.000; 514/002.000; 530/403.000; 530/417.000

NCLM: 424/193.100

NCLS: 424/093.700; 424/093.710; 424/196.110; 424/197.110; 424/204.100;

424/234.100; 424/265.100; 424/274.100; 435/069.100; 435/070.100;

435/325.000; 436/543.000; 514/002.000; 530/403.000; 530/417.000

IC ICM: A61K039-385

EXF ICS: A61K039-02; A61K039-002; A01N065-00; A01N063-00

424/193.1; 424/93.7; 424/93.71; 424/196.11; 424/197.11; 424/204.1;

424/234.1; 424/274.1; 424/265.1; 530/403; 530/417; 514/2; 436/543;

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 24 OF 54 USPTATFULL

AN 2002:115787 USPTATFULL

TI Treatment of infectious diseases with hsp90-peptide complexes

IN Srivastava, Pramod K., Riverdale, NY, United States

PA Chandawarkar, Rajiv Y., Mineola, NY, United States

PI Fordham University, Bronx, NY, United States (U.S. corporation)

US 6391306 B1 20020521

RI Division of Ser. No. US 1997-796319, filed on 7 Feb 1997, now patented,

Pat. No. US 6017540

DT Utility

FS GRANTED

LN.CNT 2367

INCL INCLM: 424/193.100

INCLS: 424/093.700; 424/093.710; 424/196.110; 424/197.110; 424/204.100;

424/234.100; 424/265.100; 424/274.100; 530/403.000; 530/417.000;

514/002.000; 436/543.000

NCLM: 424/193.100

NCLS: 424/093.700; 424/093.710; 424/196.110; 424/197.110; 424/204.100;

424/234.100; 424/265.100; 424/274.100; 436/543.000; 514/002.000;

530/403.000; 530/417.000

IC ICM: A61K039-385

EXF ICS: A61K039-00; A61K039-12; A61K039-002; A61K039-02

424/193.1; 424/93.7; 424/93.71; 424/196.11; 424/197.11; 424/204.1;

424/234.1; 424/274.1; 424/265.1; 530/403; 530/417; 514/2; 436/543

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 25 OF 54 USPTATFULL

AN 2002:108605 USPTATFULL

TI Treatment of primary and metastatic neoplastic diseases with

IN hsp90-peptide complexes

IN Srivastava, Pramod K., Riverdale, NY, United States

PA Chandawarkar, Rajiv Y., Mineola, NY, United States

PI Fordham University, Bronx, NY, United States (U.S. corporation)

US 6387374 B1 20020514

RI Division of Ser. No. US 1997-796319, filed on 7 Feb 1997

DT Utility

FS GRANTED

LN.CNT 2408

INCL INCLM: 424/193.100

INCLS: 424/277.100; 424/085.100; 424/085.700; 424/085.400; 424/093.100;

424/093.700; 424/093.710; 435/069.100; 435/070.100; 514/002.000;

530/403.000; 530/417.000; 436/543.000

NCLM: 424/193.100

NCLS: 424/085.100; 424/085.400; 424/085.700; 424/093.100; 424/093.700;

424/093.710; 424/277.100; 435/069.100; 435/070.100; 436/543.000;

514/002.000; 530/403.000; 530/417.000

IC ICM: A61K039-385

EXF ICS: A61K039-00; A23J001-00; C07K001-00; A01N065-00

424/277.1; 424/193.1; 424/85.1; 424/85.4; 424/93.1; 424/93.7;

424/93.71; 435/69.1; 435/70.1; 514/2; 530/403; 530/417; 436/543

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 26 OF 54 USPTATFULL

AN 2002:102054 USPTATFULL

TI Methods and composition for eliciting an immune response with

IN gp96-peptide complexes

IN Srivastava, Pramod K., Riverdale, NY, United States

PA Chandawarkar, Rajiv Y., Mineola, NY, United States  
 Fordham University, Bronx, NY, United States (U.S. corporation)  
 PI US 6383494 B1 20020507  
 AI US 1999-440172 19991115 (9)  
 RLI Division of Ser. No. US 1997-796319, filed on 7 Feb 1997, now patented,  
 Pat. No. US 6017540  
 DT Utility  
 FS GRANTED  
 LN.CNT 2364  
 INCL INCLM: 424/193.100  
 INCLS: 424/277.100; 424/085.100; 424/085.700; 424/085.400; 424/093.100;  
 424/093.700; 424/093.710; 424/196.110; 424/197.110; 424/204.100;  
 424/274.100; 424/265.100; 424/234.100; 514/002.000; 530/403.000;  
 530/417.000; 435/069.100; 435/070.100; 436/543.000  
 NCL NCLM: 424/193.100  
 NCLS: 424/085.100; 424/085.400; 424/085.700; 424/093.100; 424/093.700;  
 424/093.710; 424/196.110; 424/197.110; 424/204.100; 424/234.100;  
 424/265.100; 424/274.100; 424/277.100; 435/069.100; 435/070.100;  
 436/543.000; 514/002.000; 530/403.000; 530/417.000  
 IC [7]  
 ICM: A61K039-385  
 ICS: A61K039-00; A61K039-002; A61K039-18; A01N065-00  
 424/277.1; 424/85.1; 424/85.7; 424/85.4; 424/193.1; 424/93.7;  
 424/93.71; 424/274.1; 424/265.1; 424/196.11; 424/197.11; 424/204.1;  
 424/234.1; 436/543; 435/69.1; 435/70.1; 514/2; 530/403; 530/417  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 27 OF 54 USPATFULL  
 AN 2002:102053 USPATFULL  
 TI Methods and compositions for eliciting an immune response with  
 hsp70-peptide complexes  
 IN Srivastava, Pramod K., Riverdale, NY, United States  
 Chandawarkar, Rajiv Y., Mineola, NY, United States  
 PA Fordham University, Bronx, NY, United States (U.S. corporation)  
 PI US 6383493 B1 20020507  
 AI US 1999-440171 19991115 (9)  
 RLI Division of Ser. No. US 1997-796319, filed on 7 Feb 1997, now patented,  
 Pat. No. US 6017540  
 DT Utility  
 FS GRANTED  
 LN.CNT 2376  
 INCL INCLM: 424/193.100  
 INCLS: 424/277.100; 424/085.100; 424/085.700; 424/085.400; 424/093.100;  
 424/093.700; 424/093.710; 424/196.110; 424/197.110; 424/204.100;  
 424/274.100; 424/365.100; 424/234.100; 530/403.000; 530/417.000;  
 435/069.100; 435/070.100; 436/543.000; 514/002.000  
 NCL NCLM: 424/193.100  
 NCLS: 424/085.100; 424/085.400; 424/085.700; 424/093.100; 424/093.710;  
 424/196.110; 424/197.110; 424/204.100; 424/234.100; 424/265.100;  
 424/274.100; 424/277.100; 435/069.100; 435/070.100; 436/543.000;  
 514/002.000; 530/403.000; 530/417.000  
 IC [7]  
 ICM: A61K039-385  
 ICS: A61K039-00; A61K039-002; A61K039-18; A01N065-00  
 424/277.1; 424/85.1; 424/85.7; 424/85.4; 424/193.1; 424/93.7;  
 424/93.71; 424/274.1; 424/265.1; 424/196.11; 424/197.11; 424/204.1;  
 424/234.1; 435/69.1; 435/70.1; 514/2; 530/403; 530/417  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 28 OF 54 USPATFULL  
 AN 2002:102052 USPATFULL  
 TI Treatment of infectious diseases with gp96-peptide complexes  
 IN Srivastava, Pramod K., Riverdale, NY, United States  
 Chandawarkar, Rajiv Y., Mineola, NY, United States  
 PA Fordham University, Bronx, NY, United States (U.S. corporation)

PI US 6383492 B1 20020507  
 AI US 1999-439688 19991115 (9)  
 RLI Division of Ser. No. US 1997-796319, filed on 7 Feb 1997, now patented,  
 Pat. No. US 6017540  
 DT Utility  
 FS GRANTED  
 LN.CNT 2299  
 INCL INCLM: 424/193.100  
 INCLS: 424/093.700; 424/093.710; 424/196.110; 424/197.110; 424/204.100;  
 424/265.100; 424/274.100; 435/069.100; 435/070.100; 436/543.000;  
 530/403.000; 530/417.000; 514/002.000  
 NCL NCLM: 424/193.100  
 NCLS: 424/093.700; 424/093.710; 424/196.110; 424/197.110; 424/204.100;  
 424/234.100; 424/265.100; 424/274.100; 435/069.100; 435/070.100;  
 436/543.000; 514/002.000; 530/403.000; 530/417.000  
 IC [7]  
 ICM: A61K039-385  
 ICS: A61K039-02; A61K039-002; A01N065-00; A01N063-00  
 424/193.1; 424/93.7; 424/93.71; 424/196.11; 424/197.11; 424/204.1;  
 424/234.1; 424/274; 424/1; 424/265.1; 530/403; 530/417; 514/2; 436/543;  
 435/69.1; 435/70.1; 435/325  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 29 OF 54 USPATFULL  
 AN 2002:102051 USPATFULL  
 TI Prevention of infectious diseases with hsp90-peptide complexes  
 IN Srivastava, Pramod K., Riverdale, NY, United States  
 Chandawarkar, Rajiv Y., Mineola, NY, United States  
 PA Fordham University, Bronx, NY, United States (U.S. corporation)  
 PI US 6383491 B1 20020507  
 AI US 1999-439682 19991115 (9)  
 RLI Division of Ser. No. US 1997-796319, filed on 7 Feb 1997, now patented,  
 Pat. No. US 6017540  
 DT Utility  
 FS GRANTED  
 LN.CNT 2364  
 INCL INCLM: 424/193.100  
 INCLS: 424/093.700; 424/093.710; 424/196.110; 424/197.110; 424/204.100;  
 424/234.100; 424/274.100; 424/265.100; 424/265.100; 530/403.000; 530/417.000;  
 514/002.000; 436/543.000  
 NCL NCLM: 424/193.100  
 NCLS: 424/093.700; 424/093.710; 424/196.110; 424/197.110; 424/204.100;  
 424/234.100; 424/265.100; 424/274.100; 436/543.000; 514/002.000;  
 530/403.000; 530/417.000  
 IC [7]  
 ICM: A61K039-385  
 ICS: A61K039-16; A61K039-002; A61K039-02; A61K039-12  
 424/193.1; 424/93.7; 424/93.71; 424/196.11; 424/197.11; 424/204.1;  
 424/234.1; 424/274.1; 530/403; 530/417; 514/2; 436/543  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 30 OF 54 USPATFULL  
 AN 2002:95360 USPATFULL  
 TI Prevention of infectious diseases with gp96-peptide complexes  
 IN Srivastava, Pramod K., Riverdale, NY, United States  
 Chandawarkar, Rajiv Y., Mineola, NY, United States  
 PA Fordham University, Bronx, NY, United States (U.S. corporation)  
 PI US 6379672 B1 20020430  
 AI US 1999-439683 19991115 (9)  
 RLI Division of Ser. No. US 1997-796319, filed on 7 Feb 1997, now patented,  
 Pat. No. US 6017540  
 DT Utility  
 FS GRANTED  
 LN.CNT 2300  
 INCL INCLM: 424/193.100

TI		Compositions and methods for eliciting an immune response using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy Srivastava, Pramod K., Riverdale, NY, United States Fordham University, Bronx, NY, United States (U.S. corporation) US 632790 B1 20011127 AI US 1998-135712 19980818 (9) RRLI Division of Ser. No. US 1997-796316, filed on 7 Feb 1997, now patented, Pat. No. US 5830464 DT Utility FS Granted INCL LN.CNT 2321 INCL INCLS: 424/193.100 NCLM: 424/195.110; 424/196.110; 424/197.110; 424/199.700; 424/093.710; 435/325.000; 435/377.000; 435/383.000; 435/384.000; 435/385.000; 514/002.000; 530/350.000; 530/806.000; 530/807.000 NCL NCLM: 424/193.100 NCLS: 424/093.700; 424/093.710; 424/195.110; 424/196.110; 424/197.110; 435/325.000; 435/377.000; 435/383.000; 435/384.000; 435/385.000; 514/002.000; 530/350.000; 530/806.000; 530/807.000 IC [7]
L5	ANSWER 34 OF 54 USPATFULL	
AN	2001.21760 USPATFULL	
TI	Compositions and methods using complexes of heat shock protein 90 and antigenic molecules for the treatment and prevention of infectious diseases Srivastava, Pramod K., Riverdale, NY, United States Fordham University, Bronx, NY, United States (U.S. corporation) US 6187312 B1 20010213 AI US 1998-150040 19980909 (9) RILI Division of Ser. No. US 1995-527391, filed on 13 Sep 1995, now patented, Pat. No. US 5837251 DT Utility FS Granted INCL LN.CNT 2288 INCL INCLS: 424/193.100 NCLM: 424/184.100; 424/194.100; 424/196.110; 424/197.110; 424/265.100; 424/274.100; 424/277.100 NCL NCLM: 424/193.100 NCLS: 424/184.100; 424/194.100; 424/196.110; 424/197.110; 424/265.100; 424/274.100; 424/277.100 IC [7]	
L5	ANSWER 35 OF 54 USPATFULL	
AN	2000.170662 USPATFULL	
TI	Compositions and methods using complexes of heat shock protein 90 and antigenic molecules for the treatment and prevention of neoplastic diseases Srivastava, Pramod K., Riverdale, NY, United States Fordham University, Bronx, NY, United States (U.S. corporation) US 6162436 20001219 AI US 1998-150041 19980909 (9) RILI Division of Ser. No. US 1995-527391, filed on 13 Sep 1995, now patented,	
EXF	ICS: A61K039-002; A61K039-38; A61K039-385 424/184.1; 424/193.1; 424/196.11; 424/197.11; 424/265.1; 424/274.1; 424/194.1	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
L5	ANSWER 36 OF 54 USPATFULL	
AN	2000.170662 USPATFULL	
TI	Compositions and methods using complexes of heat shock protein 90 and antigenic molecules for the treatment and prevention of neoplastic diseases Srivastava, Pramod K., Riverdale, NY, United States Fordham University, Bronx, NY, United States (U.S. corporation) US 6162436 20001219 AI US 1998-150041 19980909 (9) RILI Division of Ser. No. US 1995-527391, filed on 13 Sep 1995, now patented,	
EXF	ICS: A61K039-002; A61K039-38; A61K039-385 424/184.1; 424/193.1; 424/196.11; 424/197.11; 424/265.1; 424/274.1; 424/194.1	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		



DT Pat. No. US 5837251  
FS Utility  
LN.CNT 2351  
INCL INCLM: 424/193.100  
INCLS: 424/184.100; 424/277.100; 424/085.100; 424/085.200; 424/085.500; 424/085.600; 424/085.700; 530/403.000; 530/417.000; 514/002.000; 435/810.000; 436/543.000

NCL INCLM: 424/193.100  
NCLS: 424/085.100; 424/085.200; 424/085.500; 424/085.600; 424/085.700; 424/184.100; 424/277.100; 435/810.000; 436/543.000; 514/002.000; 530/403.000; 530/417.000

IC [7]  
ICM: A61K039-00  
ICS: A61K039-002; A61K039-38; A61K039-385  
424/193.1; 424/277.1; 424/184.1; 424/85.1; 424/85.2; 424/85.5; 424/85.6; 424/85.7; 435/810; 436/543; 514/2; 530/403; 530/417

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 36 OF 54 USPATFULL  
AN 2000:164062 USPATFULL  
TI Adoptive immunotherapy using macrophages sensitized with **heat shock protein-epitope complexes**  
IN Srivastava, Pramod K., Riverdale, NY, United States  
PA Fordham University, New York, NY, United States (U.S. corporation)  
PI US 6156302 20001205  
AI US 1998-107696 19980630 (9)  
RLI Division of Ser. No. US 1995-527546, filed on 13 Sep 1995, now patented, Pat. No. US 5985270

DT Utility  
FS Granted  
LN.CNT 1511  
INCL INCLM: 424/093.100  
INCLS: 424/193.100; 424/194.100; 424/198.100; 424/204.100; 424/234.100; 424/245.100; 424/274.100; 424/085.100; 424/085.200; 424/085.500; 424/085.600; 424/085.700; 530/350.000; 530/351.000; 514/002.000

NCL INCLM: 424/093.100  
NCLS: 424/085.100; 424/085.200; 424/085.500; 424/085.600; 424/085.700; 424/193.100; 424/194.100; 424/198.100; 424/204.100; 424/234.100; 424/245.100; 424/274.100; 514/002.000; 530/350.000; 530/351.000

IC [7]  
ICM: A61K039-385; A61K045-05; C07K014-435  
ICS: A61K039-385; A61K045-05; C07K014-435  
424/198.1; 424/193.1; 424/194.1; 424/204.1; 424/234.1; 424/265.1; 424/274.1; 530/350; 530/351; 514/2

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 37 OF 54 USPATFULL  
AN 2000:149720 USPATFULL  
TI Compositions and methods using complexes of **heat shock protein gp96** and antigenic molecules for the treatment and prevention of infectious diseases  
IN Srivastava, Pramod K., Riverdale, NY, United States  
PA Fordham University, Bronx, NY, United States (U.S. corporation)  
PI US 6143299 20001107  
AI US 1998-150203 19980909 (9)  
RLI Division of Ser. No. US 1995-527391, filed on 13 Sep 1995, now patented, Pat. No. US 5837251

DT Utility  
FS Granted  
LN.CNT 2228  
INCL INCLM: 424/193.100  
INCLS: 424/184.100; 424/194.100; 424/196.110; 424/197.110; 424/265.100; 424/274.100; 424/277.100

NCLM: 424/193.100  
NCLS: 424/184.100; 424/194.100; 424/196.110; 424/197.110; 424/265.100; 424/274.100; 424/277.100

IC [7]  
ICM: A61K039-00  
ICS: A61K039-002; A61K039-38; A61K039-385  
424/193.1; 424/194.1; 424/196.11; 424/197.11; 424/265.1; 424/274.1; 424/277.100

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 38 OF 54 USPATFULL  
AN 2000:145887 USPATFULL  
TI Compositions and methods using complexes of **heat shock protein 70** and antigenic molecules for the treatment and prevention of infectious diseases  
IN Srivastava, Pramod K., Riverdale, NY, United States  
PA Fordham University, Bronx, NY, United States (U.S. corporation)  
PI US 6139841 20001031  
AI US 1998-150039 19980909 (9)  
RLI Division of Ser. No. US 1995-527391, filed on 13 Sep 1995, now patented, Pat. No. US 5837251

DT Utility  
FS Granted  
LN.CNT 2236  
INCL INCLM: 424/193.100  
INCLS: 424/184.100; 424/194.100; 424/196.110; 424/197.110; 424/265.100; 424/274.100; 424/277.100

NCLM: 424/193.100  
NCLS: 424/184.100; 424/194.100; 424/196.110; 424/197.110; 424/265.100; 424/274.100; 424/277.100

IC [7]  
ICM: A61K039-00  
ICS: A61K039-002; A61K039-38; A61K039-385  
424/184.1; 424/193.1; 424/196.11; 424/197.11; 424/265.1; 424/274.1; 424/277.100

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 39 OF 54 USPATFULL  
AN 2000:141883 USPATFULL  
TI Compositions and methods using complexes of **heat shock protein 70** and antigenic molecules for the treatment and prevention of neoplastic diseases  
IN Srivastava, Pramod K., Riverdale, NY, United States  
PA Fordham University, Bronx, NY, United States (U.S. corporation)  
PI US 6136315 20001024  
AI US 1998-150204 19980909 (9)  
RLI Division of Ser. No. US 1995-527391, filed on 13 Sep 1995, now patented, Pat. No. US 5837251

DT Utility  
FS Granted  
LN.CNT 2358  
INCL INCLM: 424/193.100  
INCLS: 424/184.100; 424/277.100; 424/085.100; 424/085.200; 424/085.500; 424/085.600; 424/085.700; 530/403.000; 530/417.000; 435/810.000; 436/543.000; 514/002.000

NCLM: 424/193.100  
NCLS: 424/085.100; 424/085.200; 424/085.500; 424/085.600; 424/085.700; 424/184.100; 424/277.100; 435/810.000; 436/543.000; 514/002.000; 530/403.000; 530/417.000

IC [7]  
ICM: A61K039-00  
ICS: A61K039-002; A61K039-38; A61K039-385  
424/193.1; 424/277.1; 424/184.1; 424/85.1; 424/85.2; 424/85.5; 424/85.6; 424/85.7; 435/810; 436/543; 514/2; 530/403; 530/417

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 40 OF 54 USPATFULL  
 AN 2000:134754 USPATFULL  
 TI Methods for generating cytotoxic T cells in vitro  
 IN Srivastava, Pramod K., Riverdale, NY, United States  
 Binder, Robert, Bronx, NY, United States  
 Blachere, Nathalie E., Bronx, NY, United States  
 PA Fordham University, Bronx, NY, United States (U.S. corporation)  
 PI US 6130087 20001010  
 AI US 1996-726967 19961007 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 1534  
 INCL INCLM: 435/372.300  
 INCLS: 435/375.000; 435/377.000  
 NCL NCLM: 435/372.300  
 NCLS: 435/375.000; 435/377.000  
 IC [7]  
 ICM: C12N005-06  
 ICS: C12N005-08  
 EXF 435/372.3; 435/377; 435/375  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 41 OF 54 USPATFULL  
 AN 2000:43771 USPATFULL  
 TI Stress protein-peptide complexes as prophylactic and therapeutic  
 IN vaccines against intracellular pathogens  
 IN Srivastava, Pramod K., Riverdale, NY, United States  
 PA Mount Sinai School of Medicine of New York University, New York, NY,  
 United States (U.S. corporation)  
 PI US 6048530 20000411  
 AI WO 9524923 19950921  
 US 1997-704727 19970619 PCT 371 date  
 WO 1995-US3311 19950316  
 RLI Continuation-in-part of Ser. No. US 1994-210421, filed on 16 Mar 1994,  
 now patented, Pat. No. US 5961979  
 DT Utility  
 FS Granted  
 LN.CNT 1967  
 INCL INCLM: 424/193.100  
 INCLS: 424/194.100; 424/196.110; 424/197.110; 424/278.100; 424/281.100;  
 424/282.200; 424/265.100; 424/274.100; 424/204.100; 424/234.100;  
 514/021.000; 530/412.000; 530/413.000; 435/069.100  
 NCL NCLM: 424/193.100  
 NCLS: 424/194.100; 424/196.110; 424/197.110; 424/204.100; 424/234.100;  
 424/265.100; 424/274.100; 424/278.100; 424/281.100; 424/282.100;  
 435/069.100; 514/021.000; 530/412.000; 530/413.000  
 IC [7]  
 ICM: A61K039-395  
 ICS: A61K039-385; A61K039-12; A61K039-02  
 EXF 530/278.1; 530/412; 530/413; 514/21; 424/281.1; 424/282.1; 424/193.1;  
 424/194.1; 424/196.11; 424/197.11; 424/265.1; 424/274.1; 424/204.1;  
 424/234.1; 435/69.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 42 OF 54 USPATFULL  
 AN 2000:24292 USPATFULL  
 TI Therapeutic and prophylactic methods using heat shock  
 IN proteins  
 IN Srivastava, Pramod K., Riverdale, NY, United States  
 PA Fordham University, Bronx, NY, United States (U.S. corporation)  
 PI US 6030618 20000229  
 AI US 1996-711918 19960910 (8)

RLI Continuation-in-part of Ser. No. US 1995-527547, filed on 13 Sep 1995,  
 now patented, Pat. No. US 5935576  
 DT Utility  
 FS Granted  
 LN.CNT 1794  
 INCL INCLM: 424/184.100  
 INCLS: 424/193.100; 424/277.100; 424/265.100; 424/274.100; 424/234.100;  
 424/204.100; 424/197.100; 424/196.100; 424/194.100; 424/085.000;  
 514/002.000; 530/300.000; 530/350.000; 530/820.000; 530/822.000;  
 530/823.000; 530/824.000; 530/825.000; 530/826.000; 530/827.000;  
 530/828.000  
 NCL NCLM: 424/184.100  
 NCLS: 424/085.100; 424/085.200; 424/085.400; 424/085.700; 424/193.100;  
 424/194.100; 424/196.110; 424/197.110; 424/204.100; 424/234.100;  
 424/265.100; 424/274.100; 424/277.100; 514/002.000; 530/300.000;  
 530/350.000; 530/820.000; 530/822.000; 530/823.000; 530/824.000;  
 530/825.000; 530/826.000; 530/827.000; 530/828.000  
 IC [7]  
 ICM: A61K038-00  
 ICS: A61K039-00; A61K035-12  
 EXF 424/184.1; 424/193.1; 424/85; 424/194.1; 424/196.11; 424/197.11;  
 424/204.1; 424/234.1; 424/274.1; 424/265.1; 424/277.1; 530/300; 530/350;  
 530/820; 530/822; 530/826; 530/825; 530/824; 530/823; 530/827; 530/828;  
 514/2

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 43 OF 54 USPATFULL  
 AN 2000:9535 USPATFULL  
 TI Composition comprising immunogenic stress protein-peptide complexes  
 IN against cancer and a cytokine  
 IN Srivastava, Pramod K., Avon, CT, United States  
 PA Mount Sinai School of Medicine of the University of New York, New York,  
 NY, United States (U.S. corporation)  
 PI US 6017544 20000125  
 AI US 1998-61365 19980416 (9)  
 RLI Division of Ser. No. US 1994-315892, filed on 30 Sep 1994, now patented,  
 Pat. No. US 5750119 which is a continuation-in-part of Ser. No. US  
 1994-180685, filed on 13 Jan 1994  
 DT Utility  
 FS Granted  
 LN.CNT 1104  
 INCL INCLM: 424/277.100  
 INCLS: 424/185.100; 424/195.110; 424/573.000; 424/085.100; 424/192.100;  
 424/198.100; 514/021.000  
 NCL NCLM: 424/277.100  
 NCLS: 424/085.100; 424/185.100; 424/192.100; 424/195.110; 424/198.100;  
 424/573.000; 514/021.000  
 IC [6]  
 ICM: A61K039-00  
 ICS: A61K039-385; A61K035-12; A61K038-00  
 EXF 424/185.1; 424/192.1; 424/85.1; 424/195.11; 424/573; 424/277.1;  
 424/198.1; 514/21  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 44 OF 54 USPATFULL  
 AN 2000:9531 USPATFULL  
 TI Prevention and treatment of primary and metastatic neoplastic diseases  
 IN and infectious diseases with heat shock/stress protein-peptide complexes  
 IN Srivastava, Pramod K., Riverdale, NY, United States  
 PA Chandawarkar, Rajiv Y., Mineola, NY, United States  
 PI Fordham University, Bronx, NY, United States (U.S. corporation)  
 US 6017540 20000125  
 AI US 1997-796319 19970207 (8)  
 DT Utility  
 FS Granted

L5	ANSWER 47 OF 54	USPATFULL	
AN	1999:120883	USPATFULL	
TI	Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens		
IN	Srivastava, Pramod K., Riverdale, NY, United States		
PA	Mount Sinai School of Medicine of the City University of New York, New York, NY, United States (U.S. corporation)		
PI	US 5961979	19991005	
AI	US 1994-210421	19940316 (8)	
DT	Utility		
FS	Granted		
LN.CNT	2491		
INCL	INCLM: 424/193.100		
	INCLM: 424/193.100; 424/191.100; 424/192.100; 424/196.110; 424/197.110; 514/002.000; 514/021.000; 530/412.000		
NCL	NCLM: 424/193.100		
	NCLM: 424/193.100; 424/191.100; 424/192.100; 424/196.110; 424/197.110; 514/002.000; 514/021.000; 530/412.000		
IC	[6]		
	ICM: A61K039-02		
	ICS: A61K039-12; A61K039-385		
EXP	514/2; 514/21; 424/193.1; 424/185.1; 424/190.1; 424/191.1; 424/192.1; 424/196.11; 424/197.11; 530/412		
CAS	INDEXING IS AVAILABLE FOR THIS PATENT.		
L5	ANSWER 48 OF 54	USPATFULL	
AN	1999:106324	USPATFULL	
TI	Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes		
IN	Srivastava, Pramod K., Avon, CT, United States		
PA	Fordham University, Bronx, NY, United States (U.S. corporation)		
PI	US 5948646	19990907	
AI	US 1997-988878	19971211 (8)	
DT	Utility		
FS	Granted		
LN.CNT	2178		
INCL	INCLM: 435/069.300		
	INCLM: 530/403.000; 536/023.100; 536/023.400; 536/023.500; 435/320.100; 435/325.000		
NCL	NCLM: 435/069.300		
	NCLM: 435/069.300; 435/320.100; 435/325.000; 530/403.000; 536/023.100; 536/023.400; 536/023.500		
IC	[6]		
	ICM: C12P021-06		
	ICS: C12N015-00		
EXP	435/69.3; 435/320.1; 435/325; 435/254.21; 435/235.1; 536/23.5; 536/23.4; 536/23.1; 530/403		
CAS	INDEXING IS AVAILABLE FOR THIS PATENT.		
L5	ANSWER 49 OF 54	USPATFULL	
AN	1999:92295	USPATFULL	
TI	Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens		
IN	Srivastava, Pramod K., Riverdale, NY, United States		
PA	Fordham University, Bronx, NY, United States (U.S. corporation)		
PI	US 5935576	19990810	
AI	US 1995-527547	19950913 (8)	
DT	Utility		
FS	Granted		
LN.CNT	1690		
INCL	INCLM: 424/184.100		
	INCLM: 424/193.100; 424/277.100; 514/002.000; 530/300.000; 530/350.000		
NCL	NCLM: 424/184.100		
	NCLM: 424/193.100; 424/277.100; 514/002.000; 530/300.000; 530/350.000		

IC [6]  
 ICM: A61K039-00  
 EXF ICS: A61K039-00; A61K035-12  
 424/184.1; 424/193.1; 424/85.1; 424/85.2; 424/85.5; 424/85.6; 424/85.7;  
 424/277.1; 435/810; 514/2; 530/350; 530/351  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 50 OF 54 CAPLUS COPYRIGHT 2002 ACS  
 AN 1999:380486 CAPLUS  
 DN 131:156694  
 TI pH-dependent peptide binding properties of the type I diabetes-associated  
 I-Ag7 molecule: rapid release of CLIP at an endosomal pH  
 AU Hausmann, Dorothee H. F.; Yu, Bei; Hausmann, Stefan; Wucherpfenning, Kai  
 W.  
 CS Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute,  
 Boston, MA, 02115, USA  
 SO Journal of Experimental Medicine (1999), 189(11), 1723-1733  
 CODEN: JEMEDV; ISSN: 0022-1007  
 PB Rockefeller University Press  
 DT Journal  
 LA English  
 RE.CNT 44  
 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 51 OF 54 USPATFULL  
 AN 1998:143661 USPATFULL  
 TI Compositions and methods using complexes of heat shock  
 proteins and antigenic molecules for the treatment and  
 prevention of neoplastic diseases  
 IN Srivastava, Pramod K.; Riverdale, NY, United States  
 PA Fordham University, Bronx, NY, United States (U.S. corporation)  
 PI US 5837251 19981117  
 AI US 1995-527391 19950913 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 2361  
 INCL INCLM: 424/193.100  
 INCLS: 424/277.100; 514/002.000; 530/403.000; 530/417.000; 436/543.000  
 NCL NCLM: 424/193.100  
 NCLS: 424/277.100; 436/543.000; 514/002.000; 530/403.000; 530/417.000  
 IC [6]  
 ICM: A61K039-385  
 EXF ICS: A61K039-00; C07K001-00; A23J001-00  
 424/184.1; 424/193.1; 424/85.1; 424/85.2; 424/85.5; 424/85.6; 424/85.7;  
 424/277.1; 435/810; 514/2; 530/403; 530/417; 436/543  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 52 OF 54 USPATFULL  
 AN 1998:134628 USPATFULL  
 TI Compositions and methods for the treatment and growth inhibition of  
 cancer using heat shock/stress protein-peptide complexes in combination  
 with adoptive immunotherapy  
 IN Srivastava, Pramod K.; Riverdale, NY, United States  
 PA Fordham University, Bronx, NY, United States (U.S. corporation)  
 PI US 5830464 19981103  
 AI US 1997-796316 19970207 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 2332  
 INCL INCLM: 424/093.710  
 INCLS: 424/085.100; 424/085.200; 424/085.500; 424/277.100; 424/278.100;  
 435/372.000; 435/384.000; 435/385.000; 435/386.000; 530/350.000  
 NCL NCLM: 424/093.710  
 NCLS: 424/085.100; 424/085.200; 424/085.500; 424/277.100; 424/278.100;  
 435/372.000; 435/384.000; 435/385.000; 435/386.000; 530/350.000

IC [6]  
 ICM: A61K039-00  
 EXF ICS: A61K045-05; C12N005-08; C07K014-435  
 424/277.1; 424/193.71; 424/85.1; 424/85.2; 424/85.5; 424/278.1; 435/372;  
 435/384; 435/385; 435/386; 530/350  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 53 OF 54 USPATFULL  
 AN 1998:51204 USPATFULL  
 TI Immunotherapeutic stress protein-peptide complexes against cancer  
 IN Srivastava, Pramod K.; Riverdale, NY, United States  
 PA Mount Sinai School of Medicine Of The City University of New York, New  
 York, NY, United States (U.S. corporation)  
 PI US 5750119 19980512  
 AI US 1994-315892 19940930 (8)  
 RLI Continuation-in-part of Ser. No. US 1994-180685, filed on 13 Jan 1994  
 DT Utility  
 FS Granted  
 LN.CNT 1097  
 INCL INCLM: 424/277.100  
 INCLS: 424/185.100; 424/195.110; 424/573.000; 514/021.000  
 NCL NCLM: 424/277.100  
 NCLS: 424/185.100; 424/195.110; 424/573.000; 514/021.000  
 IC [6]  
 ICM: A61K039-00  
 EXF ICS: A61K039-385; A61K035-12; A61K038-00  
 424/185.1; 424/192.1; 424/195.11; 424/573; 424/277.1; 514/21  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 54 OF 54 USPATFULL  
 AN 1998:34041 USPATFULL  
 TI MHC class II .beta. chain/peptide complexes useful in ameliorating  
 deleterious immune responses  
 IN Nag, Bishwajit, Pacifica, CA, United States  
 Clark, Brian R., Redwood City, CA, United States  
 Sharma, Somesh, Los Altos, CA, United States  
 McConnell, Harden, Stanford, CA, United States  
 PA Anergene Inc., Redwood City, CA, United States (U.S. corporation)  
 PI US 5734033 19980331  
 AI US 1995-483021 19950607 (8)  
 RLI Division of Ser. No. US 1995-397533, filed on 2 Mar 1995, now abandoned  
 which is a continuation of Ser. No. US 1994-208072, filed on 3 Mar 1994,  
 now abandoned which is a continuation of Ser. No. US 1992-978946, filed  
 on 18 Nov 1992, now abandoned which is a continuation-in-part of Ser.  
 No. US 1991-793938, filed on 19 Nov 1991, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 2198  
 INCL INCLM: 530/403.000  
 INCLS: 424/185.100; 424/193.100; 530/300.000; 530/395.000; 530/402.000;  
 530/868.000  
 NCL NCLM: 530/403.000  
 NCLS: 424/185.100; 424/193.100; 530/300.000; 530/395.000; 530/402.000;  
 530/868.000  
 IC [6]  
 ICM: C07K014-74  
 EXF ICS: C07K017-00; A61K039-385  
 530/300; 530/350; 530/395; 530/403; 530/868; 530/402; 424/184.1;  
 424/185.1; 424/193.1; 424/195.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s stress (a) protein  
 L7 9090 STRESS (A) PROTEIN

=> s l7 and protein (a) complex?  
L8 101 L7 AND PROTEIN (A) COMPLEX?

=> dup rem l8  
L9 88 DUP REM L8 (13 DUPLICATES REMOVED)

=> s l9 not PY=>1994  
L10 '1994' NOT A VALID FIELD CODE  
L10 8 L9 NOT PY=>1994

=> d i-8

L10 ANSWER 1 OF 8 MEDLINE  
AN 94175628 MEDLINE  
DN 94175628 PubMed ID: 8129478  
TI Rapid, early and specific diagnosis of tuberculosis and other  
mycobacterial diseases in Burundi.  
AU Barinuta I; Rigouts L; Barette M; Collart J P; De Bruyn J; Kadende P;  
Kamufu G; Douglas J T; Portaeis F  
CS Centre Hospitalo Universitaire Kamenge, Bujumbura, Burundi.  
SO ANNALES DE LA SOCIETE BELGE DE MEDECINE TROPICALE, (1993) 73 Suppl 1  
41-51.  
Journal code: 7511864. ISSN: 0365-6527.

CY Belgium  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals; AIDS  
EW 199404  
ED Entered STN: 19940420  
Last Updated on STN: 19970203  
Entered Medline: 19940414

L10 ANSWER 2 OF 8 MEDLINE  
AN 91089899 MEDLINE  
DN 91089899 PubMed ID: 2264523  
TI Microbial stress proteins.  
AU Watson K  
CS Department of Biochemistry, Microbiology and Nutrition, University of New  
England, Armidale, Australia.  
SO ADVANCES IN MICROBIAL PHYSIOLOGY, (1990) 31 183-223. Ref: 293  
Journal code: 0117147. ISSN: 0065-2911.  
CY ENGLAND: United Kingdom  
DT Journal; Article; (JOURNAL ARTICLE)  
DT General Review; (REVIEW)  
LA English  
FS Priority Journals  
EW 199102  
ED Entered STN: 19910322  
Last Updated on STN: 19910322  
Entered Medline: 19910207

L10 ANSWER 3 OF 8 CONFSCI COPYRIGHT 2002 CSA  
AN 86:20231 CONFSCI  
DN 86048012  
TI Heat stress proteins in membrane protein  
complexes  
AU Tomasovic, S.P.; Wolf, D.A.; Simonette, R.A.; Updyke, T.V.  
CS UTSCC-M.D. Anderson Hosp., Tumor Inst., Houston, TX 77030, USA  
SO Radiation Research Society. 4720 Montgomery Lane, Bethesda, MD 20014  
(USA), Abstract No. Cd-3.  
Meeting Info.: 862 5016: Radiation Research Society Thirty-Fourth Annual  
Meeting (8625016). Las Vegas, NV (USA). 12-17 Apr 1986. Radiation Research  
Society.

DT Conference  
FS DCCP  
LA UNAVAILABLE

L10 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2002 ACS  
AN 1994:104789 CAPLUS  
DN 120:104789  
TI Serum Igg antibodies to the 62-kDa heat shock protein of Helicobacter  
pylori: A pathogenic role for stress proteins in  
patients with gastritis?  
AU Engstrand, L.; Evans, D. J.; Evans, D. G.; El-Zaatari, F. A. K.; Graham,  
D. Y.  
CS Dep. Med., Veterans Aff. Med. Cent., Houston, TX, USA  
SO Immunology & Infectious Diseases (1993), 3(3), 227-30  
CODEN: IINDEK; ISSN: 0959-4957  
DT Journal  
LA English

L10 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2002 ACS  
AN 1993:54465 CAPLUS  
DN 118:54465  
TI Dissociation of complexes between 70 kDa stress proteins  
and presecretory proteins is facilitated by a cytosolic factor  
Chirico, William J.  
AU Health Sci. Cent., State Univ. New York, Brooklyn, NY, 11203, USA  
SO Biochemical and Biophysical Research Communications (1992), 189(2), 1150-6  
CODEN: BBRCA9; ISSN: 0006-291X  
DT Journal  
LA English

L10 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2002 ACS  
AN 1991:182676 CAPLUS  
DN 114:182676  
TI The two mammalian mitochondrial stress proteins, grp  
75 and hsp 58, transiently interact with newly synthesized mitochondrial  
proteins  
AU Mizzen, Lee A.; Kabling, Alma N.; Welch, William J.  
CS Dep. Med., Univ. California, San Francisco, CA, 94143, USA  
SO Cell Regulation (1991), 2(2), 165-79  
CODEN: CELREQ; ISSN: 1044-2030  
DT Journal  
LA English

L10 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2002 ACS  
AN 1989:611867 CAPLUS  
DN 111:211867  
TI Molecular spectrophotometric reaction of plant photosynthesis apparatus on  
stress conditions  
AU Saakov, V. S.; Leont'ev, V. G.  
CS Inst. Evol. Physiol. Biochem., Leningrad, USSR  
SO Colloq. Pflanzenphysiol. Humboldt-Univ. Berlin (1988), 12(Photosynth.  
Umwelt: Abhaengigkeit Photosynth. Exogener Faktoren), 143-56  
CODEN: CPBEEZ  
DT Journal; General Review  
LA German

L10 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2002 ACS  
AN 1975:55292 CAPLUS  
DN 82:55292  
TI Effect of physical load on the content of protein-bound iodine in the  
blood plasma of trained and untrained rats  
AU Tomson, K. E.; Kallikorm, A. P.  
CS Tartu. Gos. Univ., Tartu, USSR  
SO Probl. Endokrinol. (1974), 20(5), 58-61  
CODEN: PROEAS

DT Journal  
LA Russian

=> d his

(FILE 'HOME' ENTERED AT 15:43:14 ON 17 OCT 2002)

FILE 'MEDLINE, CANCERLIT, BIOSIS, CONFSCI, CAPLUS, USPATFULL' ENTERED AT 15:43:55 ON 17 OCT 2002

L1 61040 S HSP OR HEAT (A) SHOCK (A) PROTEIN  
L2 554 S L1 AND PEPTIDE (3A) ASSOCIAT?  
L3 10567 S L2 AND RELEAS? OR DISASSOCIAT?  
L4 54 S L2 AND LOW (A) PH  
L5 54 DUP REM L4 (0 DUPLICATES REMOVED)  
L6 0 S L5 NOT PY=>1994  
L7 9090 S STRESS (A) PROTEIN  
L8 101 S L7 AND PROTEIN (A) COMPLEX?  
L9 88 DUP REM L8 (13 DUPLICATES REMOVED)  
L10 8 S L9 NOT PY=>1994

=> s l1 and pharmaceutical? (a) carri?  
L1 794 L1 AND PHARMACEUTICAL? (A) CARRI?  
L2 794 L1 AND PHARMACEUTICAL? (A) CARRI?

=> dup rem l11  
PROCESSING COMPLETED FOR L11  
L12 794 DUP REM L11 (0 DUPLICATES REMOVED)

=> s l12 not PY=>1994  
'1994' NOT A VALID FIELD CODE  
L13 3 L12 NOT PY=>1994

=> d 1-3

L13 ANSWER 1 OF 3 USPATFULL  
AN 93.37709 USPATFULL  
TI Interleukin 6 antagonist peptides  
IN Scholz, Wolfgang, San Diego, CA, United States  
Chiang, Shiu-Lang, San Diego, CA, United States  
Nagarajan, Gobi, San Diego, CA, United States  
Lobl, Thomas J., Encinitas, CA, United States  
Tanabe Seiyaku Co., Ltd., Osaka, Japan (non-U.S. corporation)  
PA US 5210075 19930511  
PI US 1990-480868 19900216 (7)  
AI US 1990-480868 19900216 (7)  
DT Utility  
FS Granted  
LN.CNT 1455  
INCL INCLM: 514/014.000  
NCL INCLM: 514/013.000; 514/015.000; 530/326.000; 530/327.000; 530/328.000  
NCL INCLM: 514/014.000  
NCLM: 514/014.000  
NCLM: 514/013.000; 514/015.000; 530/326.000; 530/327.000; 530/328.000  
IC (5)  
ICM: A61K037-02  
ICS: C07K001-06; C07K001-08  
EXF 514/14: 514/13: 514/15: 530/326: 530/327: 530/328  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 2 OF 3 USPATFULL  
AN 90.36377 USPATFULL  
TI Human splenin  
IN Goldstein, Gideon, Short Hills, NJ, United States  
Aldrich, Tapan, Bridgewater, NJ, United States  
Ortho Pharmaceutical Corporation, Raritan, NJ, United States (U.S. corporation)  
PA US 4923964 19900508  
PI US 4923964

AI US 1987-53186 19870522 (7)  
DT Utility  
FS Granted  
LN.CNT 512  
INCL INCLM: 530/324.000  
INCLM: 530/301.000; 530/330.000; 514/012.000; 514/017.000; 514/021.000;  
NCLM: 530/324.000  
NCLM: 530/324.000  
NCLM: 514/012.000; 514/017.000; 514/021.000; 530/301.000; 530/330.000;  
NCLM: 530/010.000; 930/140.000  
IC (5)  
ICM: A61K037-02  
ICS: C07C103-52  
EXF 530/324: 530/330: 530/301: 514/17: 514/12: 514/121: 424/88  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 3 OF 3 USPATFULL  
AN 86.66367 USPATFULL  
TI Human seminal alpha-inhibins  
IN Li, Choh H., Berkeley, CA, United States  
Chung, David, Castro Valley, CA, United States  
Rammonds, Jr., R. Glenn, San Francisco, CA, United States  
Ramasharma, Kristipati, San Francisco, CA, United States  
The Regents of The University of California, Berkeley, CA, United States  
PA (U.S. corporation)  
PI US 4624944 19861125  
AI US 1985-745279 19850614 (6)  
DT Utility  
FS Granted  
LN.CNT 509  
INCL INCLM: 514/012.000  
INCLM: 530/324.000  
NCLM: 514/012.000  
NCLM: 530/324.000; 930/010.000; 930/110.000; 930/DIG.821  
IC (4)  
ICM: A61K037-43  
ICS: C07K007-10  
EXF 260/112.5R: 514/12: 530/324  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s his  
L14 437575 HIS  
<-----User Break----->  
=> d his

(FILE 'HOME' ENTERED AT 15:43:14 ON 17 OCT 2002)

FILE 'MEDLINE, CANCERLIT, BIOSIS, CONFSCI, CAPLUS, USPATFULL' ENTERED AT 15:43:55 ON 17 OCT 2002

L1 61040 S HSP OR HEAT (A) SHOCK (A) PROTEIN  
L2 554 S L1 AND PEPTIDE (3A) ASSOCIAT?  
L3 10567 S L2 AND RELEAS? OR DISASSOCIAT?  
L4 54 S L2 AND LOW (A) PH  
L5 54 DUP REM L4 (0 DUPLICATES REMOVED)  
L6 0 S L5 NOT PY=>1994  
L7 9090 S STRESS (A) PROTEIN  
L8 101 S L7 AND PROTEIN (A) COMPLEX?  
L9 88 DUP REM L8 (13 DUPLICATES REMOVED)  
L10 8 S L9 NOT PY=>1994  
L11 794 S L1 AND PHARMACEUTICAL? (A) CARRI?  
L12 794 DUP REM L11 (0 DUPLICATES REMOVED)  
L13 3 S L12 NOT PY=>1994

L14 437575 S HIS  
=> s l1 and administ?  
L15 4346 L1 AND ADMINIST?  
=> s l15 not PY=>1994  
L16 '1994' NOT A VALID FIELD CODE  
345 L15 NOT PY=>1994  
=> dup rem l16  
PROCESSING COMPLETED FOR L16  
L17 196 DUP REM L16 (149 DUPLICATES REMOVED)  
=> s l17 and in (a) vivo  
L18 2 L17 AND IN (A) VIVO  
=> d l18 1-2  
L18 ANSWER 1 OF 2 MEDLINE  
AN 94146753 MEDLINE  
DN 94146753 PubMed ID: 8312873  
TI Cytoprotective effects of epidermal growth factor (EGF) ointment containing nafamostat, a protease inhibitor, on tissue damage at burn sites in rats.  
AU Kiyohara Y; Nishiguchi K; Komada F; Iwakawa S; Hirai M; Okumura K  
CS Department of Hospital Pharmacy, School of Medicine, Kobe University, Japan.  
SO BIOLOGICAL AND PHARMACEUTICAL BULLETIN, (1993 Nov) 16 (11) 1146-9.  
Journal code: 9311984. ISSN: 0918-6158.  
CY Japan  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199403  
ED Entered STN: 19940330  
Last Updated on STN: 20000303  
Entered Medline: 19940318  
L18 ANSWER 2 OF 2 MEDLINE  
AN 91005536 MEDLINE  
DN 91005536 PubMed ID: 2119984  
TI Mutations affecting beta-alanine metabolism influence inducibility of the 93D puff by heat shock in *Drosophila melanogaster*.  
AU Lakhotia S C; Chowdhuri D K; Burma P K  
CS Department of Zoology, Banaras Hindu University, Varanasi, India.  
SO CHROMOSOMA, (1990 Aug) 99 (4) 296-305.  
Journal code: 23851388. ISSN: 0009-5915.  
CY GERMANY; Germany, Federal Republic of  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199011  
ED Entered STN: 19910117  
Last Updated on STN: 19910117  
Entered Medline: 19901109  
=> d l18 2 all  
L18 ANSWER 2 OF 2 MEDLINE  
AN 91005536 MEDLINE  
DN 91005536 PubMed ID: 2119984  
TI Mutations affecting beta-alanine metabolism influence inducibility of the 93D puff by heat shock in *Drosophila melanogaster*.  
AU Lakhotia S C; Chowdhuri D K; Burma P K

CS Department of Zoology, Banaras Hindu University, Varanasi, India.  
SO CHROMOSOMA, (1990 Aug) 99 (4) 296-305.  
Journal code: 23851388. ISSN: 0009-5915.  
CY GERMANY; Germany, Federal Republic of  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199011  
ED Entered STN: 19910117  
Last Updated on STN: 19910117  
Entered Medline: 19901109  
AB Effect of mutations at the ebony or black locus on induction of heat shock puffs in polytene nuclei of salivary glands of *Drosophila melanogaster* larvae were examined by [3H]uridine autoradiography. The levels of beta-alanine in the body are known to be increased by mutation at the ebony locus but decreased by mutation at the black locus. The presence of mutant allele/s at either locus in the homo- or heterozygous condition prevented induction of the 93D puff by heat shock. Elimination of the mutant allele at the ebony or black locus by recombination or by reversal of a P element insertion mutant allele of ebony restored the heat shock inducibility of the 93D puff. In vivo or in vitro administration of excess beta-alanine to salivary glands of wild-type larvae also resulted in the 93D site being refractory to heat shock induction. In agreement with earlier results, non-induction of the 93D puff during heat shock due to the beta-alanine effect was accompanied by unequal puffing of the 87A and 87C loci. The selective inducibility of the 93D puff by benzamide was not affected by ebony or black mutations or by excess beta-alanine in wild-type larvae.  
Check Tags: Animal; Support, Non-U.S. Gov't  
Alleles  
Benzamides: PD, pharmacology  
\*Chromosomes: ME, metabolism  
Chromosomes: UL, ultrastructure  
\**Drosophila melanogaster*: GE, genetics  
\*Genes  
Genotype  
Heat  
Heat-Shock Proteins: ME, metabolism  
\*Mutation  
Nucleic Acid Hybridization  
Phenotype  
\*beta-Alanine: ME, metabolism  
RN 107-95-9 (beta-Alanine): 27208-38-4 (benzamide)  
CN 0 (Benzamides); 0 (Heat-Shock Proteins)  
=> d his  
(FILE 'HOME' ENTERED AT 15:43:14 ON 17 OCT 2002)  
FILE 'MEDLINE, CANCERLIT, BIOSIS, CONFSCI, CAPLUS, USPATFULL' ENTERED AT 15:43:55 ON 17 OCT 2002  
61040 S HSP OR HEAT (A) SHOCK (A) PROTEIN  
L1 554 S L1 AND PEPTIDE (3A) ASSOCIAT?  
L2 10567 S L2 AND RELEASE? OR DISASSOCIAT?  
L3 54 S L2 AND LOW (A) PH  
L4 54 DUP REM L4 (0 DUPLICATES REMOVED)  
L5 0 S L5 NOT PY=>1994  
L6 9090 S STRESS (A) PROTEIN  
L7 101 S L7 AND PROTEIN (A) COMPLEX?  
L8 88 DUP REM L8 (13 DUPLICATES REMOVED)  
L9 8 S L9 NOT PY=>1994  
L10 794 S L1 AND PHARMACEUTICAL? (A) CARRI?  
L11 794 DUP REM L11 (0 DUPLICATES REMOVED)  
L12 3 S L12 NOT PY=>1994  
L13

L14 437575 S HIS  
 L15 4346 S L1 AND ADMINIST?  
 L16 345 S L15 NOT PY=>1994  
 L17 196 DUP REM L16 (149 DUPLICATES REMOVED)  
 L18 2 S L17 AND IN (A) VIVO  
 => s l1 and pharmaceutical (a) compound or composition  
 L19 2944825 L1 AND PHARMACEUTICAL (A) COMPOUND OR COMPOSITION  
 => s l1 and pharmaceutical (a) compound  
 L20 129 L1 AND PHARMACEUTICAL (A) COMPOUND  
 => dup rem L20  
 PROCESSING COMPLETED FOR L20  
 L21 128 DUP REM L20 (1 DUPLICATE REMOVED)  
 => s l21 not PY=>1994  
 '1994' NOT A VALID FIELD CODE  
 L22 0 L21 NOT PY=>1994  
 => s l21 not PY=>1995  
 '1995' NOT A VALID FIELD CODE  
 L23 0 L21 NOT PY=>1995  
 <-----User Break----->  
 u  
 SEARCH ENDED BY USER  
 L24 296 L1 AND PEPTIDE COMPLEX  
 => s l23 and peptide (a) complex  
 L25 0 L23 AND PEPTIDE (A) COMPLEX  
 <-----User Break----->  
 u  
 SEARCH ENDED BY USER  
 L26 478 L1 AND PEPTIDE (A) COMPLEX  
 => s l1 and peptide (a) complex  
 L27 312 DUP REM L26 (166 DUPLICATES REMOVED)  
 => s l27 and dissociat?  
 L28 76 L27 AND DISSOCIAT?  
 => d 1-76  
 L28 ANSWER 1 OF 76 MEDLINE  
 AN 2001403568 MEDLINE  
 DN 21347922 PubMed ID: 11352903  
 TI Characterization of a lidless form of the molecular chaperone DnaK:  
 deletion of the lid increases peptide on- and off-rate constants.  
 AU Buczynski G; Slepnev S V; Sehorn M G; Witt S N  
 CS Department of Biochemistry and Molecular Biology, Louisiana State  
 University Health Sciences Center, Shreveport, Louisiana 71130-3932, USA.  
 SO JOURNAL OF BIOLOGICAL CHEMISTRY. (2001 Jul 20) 276 (29) 27231-6.  
 CY Journal code: 2985121R. ISSN: 0021-9258.  
 DT United States  
 LA English  
 FS Priority Journals  
 EM 200108  
 ED Entered STN: 20010827  
 Last Updated on STN: 20010827

L28 ANSWER 2 OF 76 MEDLINE  
 AN 2001212381 MEDLINE  
 DN 21103186 PubMed ID: 11160214  
 TI A role for calnexin in the assembly of the MHC class I loading complex in  
 the endoplasmic reticulum.  
 AU Diedrich G; Bangia N; Pan M; Cresswell P  
 CS Section of Immunobiology, Howard Hughes Medical Institute, Yale University  
 School of Medicine, New Haven, CT 06510, USA.  
 SO JOURNAL OF IMMUNOLOGY. (2001 Feb 1) 166 (3) 1703-9.  
 CY Journal code: 2985117R. ISSN: 0022-1767.  
 DT United States  
 LA English  
 FS Abridged Index Medicus Journals; Priority Journals  
 EM 200104  
 ED Entered STN: 20010425  
 Last Updated on STN: 20021012  
 Entered Medline: 20010419

L28 ANSWER 3 OF 76 MEDLINE  
 AN 2000012548 MEDLINE  
 DN 20012548 PubMed ID: 10547057  
 TI ATP lowers the activation enthalpy barriers to DnaK-peptide  
 complex formation and dissociation.  
 AU Farr C D; Witt S N  
 CS Department of Biochemistry and Molecular Biology, Louisiana State  
 University Medical Center, Shreveport 71130, USA.  
 NC GM51521 (NIGMS)  
 SO CELL STRESS AND CHAPERONES. (1999 Jun) 4 (2) 77-85.  
 CY Journal code: 9610925. ISSN: 1355-8145.  
 DT United States  
 LA English  
 FS Priority Journals  
 EM 199911  
 ED Entered STN: 20000111  
 Last Updated on STN: 20000111  
 Entered Medline: 19991119

L28 ANSWER 4 OF 76 MEDLINE  
 AN 97346285 MEDLINE  
 DN 97346285 PubMed ID: 9202705  
 TI Purification of immunogenic heat shock protein  
 70-peptide complexes by ADP-affinity chromatography.  
 AU Peng P; Menoret A; Srivastava P K  
 CS Center for Immunotherapy of Cancer and Infectious Diseases, University of  
 Connecticut School of Medicine, Farmington 06030, USA.  
 NC CA44786 (NCI)  
 SO JOURNAL OF IMMUNOLOGICAL METHODS. (1997 May 12) 204 (1) 13-21.  
 CY Journal code: 1305440. ISSN: 0022-1759.  
 DT Netherlands  
 LA English  
 FS Priority Journals  
 EM 199707  
 ED Entered STN: 19970805  
 Last Updated on STN: 19970805  
 Entered Medline: 19970722

L28 ANSWER 5 OF 76 MEDLINE  
 AN 97094880 MEDLINE  
 DN 97094880 PubMed ID: 8940114



TI Binding of an N-terminal rhodanese peptide to DnaJ and to ribosomes.  
AU Kudlicki W; Odom O W; Kramer G; Hardesty B  
CS Department of Chemistry and Biochemistry, The University of Texas, Austin,  
Texas 78712, USA.  
SO JOURNAL OF BIOLOGICAL CHEMISTRY, (1996 Dec 6) 271 (49) 31160-5.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199701  
ED Entered STN: 19970128  
Last Updated on STN: 19970128  
Entered Medline: 19970109

L28 ANSWER 6 OF 76 MEDLINE  
AN 96082149 MEDLINE  
DN 96082149 PubMed ID: 7492560  
TI Large activation energy barriers to chaperone-peptide  
complex formation and dissociation.  
AU Farr C D; Galiano F J; Witt S N  
CS Department of Biochemistry and Molecular Biology, Louisiana State  
University Medical Center, Shreveport 71130-3932, USA.  
NC GM51521-02 (NIGMS)  
SO BIOCHEMISTRY, (1995 Nov 28) 34 (47) 15574-82.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199601  
ED Entered STN: 19960217  
Last Updated on STN: 19970203  
Entered Medline: 19960111

L28 ANSWER 7 OF 76 MEDLINE  
AN 96064757 MEDLINE  
DN 96064757 PubMed ID: 7592894  
TI In vitro dissociation of BIP-peptide complexes  
requires a conformational change in BIP after ATP binding but does not  
require ATP hydrolysis.  
AU Wei J; Gaut J R; Hendershot L M  
CS Department of Tumor Cell Biology, St Jude Children's Research Hospital,  
Memphis, Tennessee 38105, USA.  
NC CA 21765 (NCI)  
SO JOURNAL OF BIOLOGICAL CHEMISTRY, (1995 Nov 3) 270 (44) 26677-82.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199512  
ED Entered STN: 19960124  
Last Updated on STN: 19970203  
Entered Medline: 19951221

L28 ANSWER 8 OF 76 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
AN 2002-77509 BIOSIS  
DN PREV200200077609  
TI Reconstituted heat shock protein-  
peptide complex in vitro and induction of  
peptide-specific cytotoxic T lymphocyte response of hepatocellular  
carcinoma.  
AU Guo Ailin (1); Sui Yanfang (1); Zhang Lihong (1); et al

CS (1) Department of Pathology, Fourth Military Medical University, Xi'an  
China  
SO Zhongguo Zhongliu Linchuang, (Oct. 20, 2001) Vol. 28, No. 10, pp. 725-728.  
print.  
ISSN: 1000-8179.  
DT Article  
LA Chinese

L28 ANSWER 9 OF 76 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
AN 1997-268254 BIOSIS  
DN PREV199799559972  
TI Purification of immunogenetic heat shock  
protein 70-peptide complexes by ADP-affinity  
chromatography.  
AU Peng, Ping; Menoret, Antoine; Srivastava, Pramod K. (1)  
CS (1) Cent. Immunotherapy Cancer Infectious Diseases, Univ. Connecticut Sch.  
Med., Farmington, CT 06030 USA  
SO Journal of Immunological Methods, (1997) Vol. 203, No. 1, pp. 13-21.  
ISSN: 0022-1759.  
DT Article  
LA English

L28 ANSWER 10 OF 76 CAPLUS COPYRIGHT 2002 ACS  
AN 1999-380486 CAPLUS  
DN 131-156694  
TI pH-dependent peptide binding properties of the type I diabetes-associated  
I-Ag7 molecule: rapid release of CLIP at an endosomal pH  
AU Hausmann, Dorothee H. F.; Yu, Bei; Hausmann, Stefan; Wucherpfennig, Kai  
W.  
CS Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute,  
Boston, MA, 02115, USA  
SO Journal of Experimental Medicine (1999), 189(11), 1723-1733  
CODEN: JEMEDV; ISSN: 0022-1007  
PB Rockefeller University Press  
DT Journal  
LA English

RE CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 11 OF 76 CAPLUS COPYRIGHT 2002 ACS  
AN 1996-494588 CAPLUS  
DN 125-325646  
TI Synthetic peptides non-covalently bound to bacterial hap 70  
elicit peptide-specific T-cell responses in vivo  
AU Roman, E.; Moreno, C.  
CS MRC Tuberculosis Related Infections Unit, Royal Postgraduate Med. Sch.,  
London, UK  
SO Immunology (1996), 88(4), 487-492  
CODEN: IMMUAJ; ISSN: 0019-2805  
PB Blackwell  
DT Journal  
LA English

L28 ANSWER 12 OF 76 USPATFULL  
AN 2002-273576 USPATFULL  
TI Immune mediators and related methods  
IN Kindsvogel, Wayne, Seattle, WA, UNITED STATES  
Reich, Eva Pia, Palo Alto, CA, UNITED STATES  
Gross, Jane A., Seattle, WA, UNITED STATES  
Deshpande, Shrinkant, Fremont, CA, UNITED STATES  
Sheppard, Paul O., Redmond, WA, UNITED STATES  
Corixa Corp., Seattle, WA, UNITED STATES, 98104 (U.S. corporation)  
PA US 2002151707 AI 20021017  
PI US 2002-81281 AI 20020220 (10)  
RLI Continuation of Ser. No. US 1999-361811, filed on 3 Mar 1999, PENDING

Continuation of Ser. No. US 1996-657581, filed on 7 Jun 1996, ABANDONED  
Continuation of Ser. No. US 1995-480002, filed on 7 Jun 1995, ABANDONED  
Continuation of Ser. No. US 1995-483241, filed on 7 Jun 1995, ABANDONED  
Continuation of Ser. No. US 1995-482133, filed on 7 Jun 1995, ABANDONED  
US 1995-5964P 19951027 (60)  
PRAI DT Utility  
FS APPLICATION  
LN.CNT 4579  
INCL INCLM: 536/023.500  
INCLS: 530/350.000; 435/069.100; 435/320.100; 435/325.000  
NCL NCLM: 536/023.500  
NCLS: 530/350.000; 435/069.100; 435/320.100; 435/325.000  
IC [7]  
ICM: C07K014-74  
ICS: C12P021-02; C12N005-06; C07H021-04

L28 ANSWER 13 OF 76 USPATFULL  
AN 2002:273364 USPATFULL  
TI Testis specific protein  
IN Konklin, Darrell C., Seattle, WA, UNITED STATES  
Feidhaus, Andrew L., Lynnwood, WA, UNITED STATES  
Holderman, Susan D., Seattle, WA, UNITED STATES  
ZymoGenetics, Inc. (U.S. corporation)  
PA US 2002151492 A1 20021017  
PI US 2001-1632 A1 20011025 (10)  
AI US 2001-1632 A1 20011025 (10)  
RLI Continuation of Ser. No. US 2000-541919, filed on 3 Apr 2000, PENDING  
PRAI US 1999-166040P 19991117 (60)  
US 1999-128210P 19990407 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 4099  
INCL INCLM: 514/012.000  
INCLS: 530/324.000; 435/069.100; 435/325.000; 435/320.100; 536/023.500  
NCL NCLM: 514/012.000  
NCLS: 530/324.000; 435/069.100; 435/325.000; 435/320.100; 536/023.500  
IC [7]  
ICM: A61K038-17  
ICS: C07H021-04; C12P021-02; C12N005-06; C07K014-435

L28 ANSWER 14 OF 76 USPATFULL  
AN 2002:272908 USPATFULL  
TI Human serine protease  
IN Holloway, James L., Seattle, WA, UNITED STATES  
PI US 2002151029 A1 20021017  
AI US 2001-981123 A1 20011016 (9)  
RLI Continuation of Ser. No. US 2000-715994, filed on 17 Nov 2000, PENDING  
PRAI US 1999-167038P 19991123 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3450  
INCL INCLM: 435/226.000  
INCLS: 530/388.260; 435/069.100; 435/325.000; 435/320.100; 536/023.200  
NCL NCLM: 435/226.000  
NCLS: 530/388.260; 435/069.100; 435/325.000; 435/320.100; 536/023.200  
IC [7]  
ICM: C12N009-64  
ICS: C07H021-04; C12P021-02; C12N005-06; C07K016-40

L28 ANSWER 15 OF 76 USPATFULL  
AN 2002:272892 USPATFULL  
TI Zalp1a3: a human secreted protein  
IN Konklin, Darrell C., Seattle, WA, UNITED STATES  
Gao, Zeren, Redmond, WA, UNITED STATES  
PA ZymoGenetics, Inc. (U.S. corporation)  
PI US 2002151013 A1 20021017

US 2001-999678 A1 20011031 (9)  
RLI Continuation of Ser. No. US 2000-551632, filed on 18 Apr 2000, PENDING  
PRAI US 1999-130235P 19990420 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3804  
INCL INCLM: 435/183.000  
INCLS: 435/069.100; 435/325.000; 435/320.100; 536/023.200  
NCL NCLM: 435/183.000  
NCLS: 435/069.100; 435/325.000; 435/320.100; 536/023.200  
IC [7]  
ICM: C12N009-00  
ICS: C07H021-04; C12P021-02; C12N005-06

L28 ANSWER 16 OF 76 USPATFULL  
AN 2002:272853 USPATFULL  
TI Placental protein having multiple EGF-like domains  
IN Holloway, James L., Seattle, WA, UNITED STATES  
Heffernan, Jane K., Seattle, WA, UNITED STATES  
Taft, David W., Seattle, WA, UNITED STATES  
PI US 2002150974 A1 20021017  
AI US 2001-901940 A1 20010709 (9)  
PRAI US 2000-218004P 20000712 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 4052  
INCL INCLM: 435/069.100  
INCLS: 435/325.000; 435/320.100; 435/252.300; 435/254.200; 536/023.200;  
NCL NCLM: 435/069.100  
NCLS: 435/325.000; 435/320.100; 435/252.300; 435/254.200; 536/023.200;  
IC [7]  
ICM: C07H021-04  
ICS: C12P021-02; C12N005-06; C07K014-475; C12N001-21; C12N001-18

L28 ANSWER 17 OF 76 USPATFULL  
AN 2002:272801 USPATFULL  
TI Compositions and methods for the therapy and diagnosis of colon cancer  
IN Stoik, John A., Bothell, WA, UNITED STATES  
Xu, Jiangchun, Bellevue, WA, UNITED STATES  
Chenault, Ruth A., Seattle, WA, UNITED STATES  
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES  
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)  
PI US 2002150922 A1 20021017  
AI US 2001-998598 A1 20011116 (9)  
PRAI US 2001-304037P 20010710 (60)  
US 2001-279670P 20010328 (60)  
US 2001-267011P 20010206 (60)  
US 2000-252222P 20001120 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 9233  
INCL INCLM: 435/006.000  
INCLS: 435/007.230; 435/069.100; 435/183.000; 435/320.100; 435/325.000;  
NCL NCLM: 435/006.000  
NCLS: 435/007.230; 435/069.100; 435/183.000; 435/320.100; 435/325.000;  
IC [7]  
ICM: C12Q001-68  
ICS: G01N033-574; C07H021-04; C12N009-00; C12P021-02; C12N005-06

L28 ANSWER 18 OF 76 USPATFULL  
AN 2002:266425 USPATFULL

TI Human vomeronasal receptor  
 IN Holloway, James L., Seattle, WA, UNITED STATES  
 PI Lok, Si, Seattle, WA, UNITED STATES  
 US 2002147308 A1 20021010  
 AI US 2001-948078 A1 20010906 (9)  
 PRAI US 2000-230409P 20000906 (60)  
 US 2000-257129P 20001220 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 3501  
 INCL INCLM: 530/350.000  
 NCL NCLM: 530/350.000  
 IC [7]  
 ICM: C07K001-00  
 ICS: C07K014-00; C07K017-00  
  
 L28 ANSWER 19 OF 76 USPTAFULL  
 AN 2002:265890 USPTAFULL  
 TI Human vomeronasal receptor-3  
 IN Holloway, James L., Seattle, WA, UNITED STATES  
 PI Lok, Si, Seattle, WA, UNITED STATES  
 US 2002146766 A1 20021010  
 AI US 2001-947744 A1 20010906 (9)  
 PRAI US 2000-230977P 20000907 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 3343  
 INCL INCLM: 435/069.100  
 INCLS: 435/325.000; 435/320.100; 530/350.000; 530/388.220; 536/023.500  
 NCL NCLM: 435/069.100  
 NCLS: 435/325.000; 435/320.100; 530/350.000; 530/388.220; 536/023.500  
 IC [7]  
 ICM: C07K014-705  
 ICS: C12P021-06; C07H021-04; C12P021-02; C12N005-06; C07K016-28  
  
 L28 ANSWER 20 OF 76 USPTAFULL  
 AN 2002:265887 USPTAFULL  
 TI Murine cytokine receptor  
 IN Gao, Zeren, Redmond, WA, UNITED STATES  
 PI US 2002146763 A1 20021010  
 AI US 2001-899471 A1 20010705 (9)  
 PRAI US 2000-216446P 20000706 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 4404  
 INCL INCLM: 435/069.100  
 INCLS: 435/325.000; 435/320.100; 435/235.100; 530/350.000; 530/388.220; 536/023.500  
 NCL NCLM: 435/069.100  
 NCLS: 435/325.000; 435/320.100; 435/235.100; 530/350.000; 530/388.220; 536/023.500  
 IC [7]  
 ICM: C07K014-715  
 ICS: C07K016-28; C12P021-02; C12N005-06; C12N007-00; C07H021-04  
  
 L28 ANSWER 21 OF 76 USPTAFULL  
 AN 2002:265881 USPTAFULL  
 TI Novel nucleic acids and polypeptides  
 IN Tang, Y. Tom, San Jose, CA, UNITED STATES  
 Zhou, Ping, Cupertino, CA, UNITED STATES  
 Goodrich, Ryle, San Jose, CA, UNITED STATES  
 Asundi, Vinod, Foster City, CA, UNITED STATES  
 Zhao, Qing A., San Jose, CA, UNITED STATES  
 Wang, Jian-Rui, Cupertino, CA, UNITED STATES  
 Xue, Aidong J., Sunnyvale, CA, UNITED STATES

Ren, Feiyan, Cupertino, CA, UNITED STATES  
 Wang, Dunrui, Poway, CA, UNITED STATES  
 Chen, Rui-Hong, Foster City, CA, UNITED STATES  
 Dmanac, Radoje T., Palo Alto, CA, UNITED STATES  
 US 2002146757 A1 20021010  
 AI US 2001-808701 A1 20010314 (9)  
 RLI Continuation-in-part of Ser. No. US 2000-649167, filed on 23 Aug 2000,  
 PENDING Continuation-in-part of Ser. No. US 2000-540217, filed on 31 Mar  
 2000, PENDING  
 DT Utility  
 FS APPLICATION  
 LN.CNT 6734  
 INCL INCLM: 435/069.100  
 INCLS: 435/325.000; 435/320.100; 435/183.000; 530/388.100; 514/012.000;  
 NCL NCLM: 536/023.200  
 NCLS: 435/069.100; 435/325.000; 435/320.100; 435/183.000; 530/388.100; 514/012.000;  
 536/023.200  
 IC [7]  
 ICM: A61K038-17  
 ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06; C07K016-40  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L28 ANSWER 22 OF 76 USPTAFULL  
 AN 2002:265924 USPTAFULL  
 TI Methods for use of apoptotic cells to deliver antigen to dendritic cells  
 IN Albert, Matthew L., New York, NY, UNITED STATES  
 Bhardwaj, Nina, West Orange, NJ, UNITED STATES  
 Steinman, Ralph M., Westport, CT, UNITED STATES  
 Inaba, Kayo, Kyoto, JAPAN  
 US 2002146396 A1 20021010  
 AI US 2001-148777 A1 20011211 (10)  
 RLI Continuation of Ser. No. US 1999-251896, filed on 19 Feb 1999, PENDING  
 PRAI US 1998-75356P 19980220 (60)  
 US 1998-77095P 19980306 (60)  
 US 1998-101749P 19980924 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 3220  
 INCL INCLM: 424/093.210  
 INCLS: 435/366.000; 435/456.000  
 NCL NCLM: 424/093.210  
 NCLS: 435/366.000; 435/456.000  
 IC [7]  
 ICM: A61K048-00  
 ICS: C12N005-08; C12N015-86  
  
 L28 ANSWER 23 OF 76 USPTAFULL  
 AN 2002:259572 USPTAFULL  
 TI Human vomeronasal receptor-4  
 IN Lok, Si, Seattle, WA, UNITED STATES  
 Holloway, James L., Seattle, WA, UNITED STATES  
 PI US 2002143148 A1 20021003  
 AI US 2001-947871 A1 20010906 (9)  
 PRAI US 2000-230975P 20000907 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 3349  
 INCL INCLM: 530/350.000  
 INCLS: 530/388.220; 435/069.100; 435/320.100; 435/325.000; 536/023.500  
 NCL NCLM: 530/350.000  
 NCLS: 530/388.220; 435/069.100; 435/320.100; 435/325.000; 536/023.500  
 IC [7]  
 ICM: C07K014-705

ICS: C07H021-04; C12P021-02; C12N005-06; C07K016-28

L28 ANSWER 24 OF 76 USPTATFULL  
AN 2002:258826 USPTATFULL  
TI Mammalian cystatin-8 and its use to inhibit cancer procoagulant protein  
IN Holloway, James L., Seattle, WA, UNITED STATES  
Gao, Zeren, Redmond, WA, UNITED STATES  
Bishop, Paul D., Fall City, WA, UNITED STATES  
PI US 2002142396 AI 20021003  
AI US 2001-941314 AI 20010829 (9)  
PRAI US 2000-230230P 20000901 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3571  
INCL INCLM: 435/069.500  
INCL: 530/351.000; 424/085.100; 530/388.240; 536/023.500  
NCL NCLM: 435/069.500  
NCL: 530/351.000; 424/085.100; 530/388.240; 536/023.500  
IC [7]  
ICM: A61K038-19  
ICS: C12P021-02; C07K014-52; C07K016-24; C07H021-04

L28 ANSWER 25 OF 76 USPTATFULL  
AN 2002:254045 USPTATFULL  
TI Molecular complexes which modify immune responses  
IN Schneck, Jonathan, Silver Spring, MD, United States  
O'Herrin, Sean, Madison, WI, United States  
Lebowitz, Michael S., Pikesville, MD, United States  
Hamad, Abdel, Ellicott City, MD, United States  
PA The Johns Hopkins University, Baltimore, MD, United States (U.S. corporation)  
PI US 6458354 BI 20021001  
AI US 2000-668143 20000925 (9)  
RLI Continuation-in-part of Ser. No. US 1999-324782, filed on 3 Jun 1999  
Continuation-in-part of Ser. No. US 1998-63276, filed on 21 Apr 1998,  
now patented, Pat. No. US 6140113 Continuation-in-part of Ser. No. US  
1997-828712, filed on 28 Mar 1997  
PRAI US 1996-14367P 19960328 (60)  
DT Utility  
FS GRANTED  
LN.CNT 2579  
INCL INCLM: 424/134.100  
INCL: 424/130.100; 424/139.100; 424/141.100; 514/002.000; 514/012.000;  
530/350.000; 530/387.300; 530/388.100  
NCL NCLM: 424/134.100  
NCL: 424/130.100; 424/139.100; 424/141.100; 514/002.000; 514/012.000;  
530/350.000; 530/387.300; 530/388.100  
IC [7]  
ICM: A61K039-395  
ICS: C07K016-100; C12P021-08  
EXF 424/130.1; 424/134.1; 424/139.1; 424/141.1; 514/12; 514/2; 530/350;  
530/387.3; 530/388.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 26 OF 76 USPTATFULL  
AN 2002:251214 USPTATFULL  
TI Human pheromone polypeptides  
IN Lok Si, Seattle, WA, UNITED STATES  
Holloway, James L., Seattle, WA, UNITED STATES  
O'Hara, Patrick J., Seattle, WA, UNITED STATES  
PI US 2002137159 AI 20020926  
AI US 2001-934814 AI 20010822 (9)  
PRAI US 2000-229656P 20000831 (60)  
US 2000-23226P 20000913 (60)  
DT Utility

FS APPLICATION  
LN.CNT 4100  
INCL INCLM: 435/183.000  
INCL: 435/069.100; 435/325.000; 435/320.100; 536/023.200  
NCL NCLM: 435/183.000  
NCL: 435/069.100; 435/325.000; 435/320.100; 536/023.200  
IC [7]  
ICM: C12N009-00  
ICS: C07H021-04; C12P021-02; C12N005-06  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 27 OF 76 USPTATFULL  
AN 2002:246727 USPTATFULL  
TI Stress protein-peptide complexes as prophylactic and  
therapeutic vaccines against intracellular pathogens  
IN Srivastava, Pramod K., Riverdale, NY, United States  
PA Mount Sinai School of Medicine of New York University, New York, NY,  
United States (U.S. corporation)  
PI US 6455503 BI 20020924  
AI US 1999-412420 19991005 (9)  
RLI Continuation of Ser. No. US 704727, now patented, Pat. No. US 6048530  
Continuation-in-part of Ser. No. US 1994-210421, filed on 16 Mar 1994,  
now patented, Pat. No. US 5961979, issued on 5 Oct 1999  
DT Utility  
FS GRANTED  
LN.CNT 1847  
INCL INCLM: 514/021.000  
INCL: 424/193.100; 424/002.000; 530/344.000; 530/806.000; 530/403.000;  
530/300.000; 530/350.000; 514/002.000; 514/012.000; 436/823.000  
NCL NCLM: 514/021.000  
NCL: 424/193.100; 424/002.000; 530/344.000; 530/806.000; 530/403.000;  
530/300.000; 530/350.000; 514/002.000; 514/012.000; 436/823.000  
IC [7]  
ICM: A61K038-00  
ICS: C07K001-00; C07K001-14; C07K002-00; C07K004-12  
424/193.1; 530/300; 530/350; 530/344; 530/806; 530/403; 514/2; 514/12;  
514/21; 436/823  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 28 OF 76 USPTATFULL  
AN 2002:243802 USPTATFULL  
TI Secretory protein-48  
IN Lok, Si, Seattle, WA, UNITED STATES  
Sheppard, Paul O., Granite Falls, WA, UNITED STATES  
Kindsvogel, Wayne, Seattle, WA, UNITED STATES  
Bort, Susan J., Seattle, WA, UNITED STATES  
PA ZymoGenetics, Inc. (U.S. corporation)  
PI US 2002132996 AI 20020919  
AI US 2001-955807 AI 20010919 (9)  
RLI Continuation of Ser. No. US 1999-410603, filed on 1 Oct 1999, ABANDONED  
PRAI US 1998-102679P 19981001 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 4057  
INCL INCLM: 536/023.100  
INCL: 530/324.000; 530/387.900; 530/387.200  
NCL NCLM: 536/023.100  
NCL: 530/324.000; 530/387.900; 530/387.200  
IC [7]  
ICM: C07H021-02  
ICS: C07H021-04; C07K005-00; C07K007-00; C07K016-00; C07K017-00;  
A61K038-00; C12P021-08  
L28 ANSWER 29 OF 76 USPTATFULL  
AN 2002:243051 USPTATFULL

TI Compositions and methods for the therapy and diagnosis of ovarian cancer  
IN Algate, Paul A., Issaquah, WA, UNITED STATES  
Jones, Robert, Seattle, WA, UNITED STATES  
Harlocker, Susan L., Seattle, WA, UNITED STATES  
PA Corixa Corporation, Seattle, WA, 98104 (U.S. corporation)  
PI US 2002132237 AI 20020919  
AI US 2001-867701 AI 20010529 (9)  
PRAI US 2000-207484P 20000526 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 25718  
INCL INCLM: 435/006.000  
INCLS: 435/091.200  
NCL INCLM: 435/006.000  
NCLS: 435/091.200  
IC [7]  
ICS: C12Q001-68  
ICM: C12P019-34  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 30 OF 76 USPTAFULL  
AN 2002:242791 USPTAFULL  
TI Compositions and methods for the therapy and diagnosis of colon cancer  
IN King, Gordon E., Shoreline, WA, UNITED STATES  
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES  
Xu, Jiangchun, Bellevue, WA, UNITED STATES  
Secretist, Heather, Seattle, WA, UNITED STATES  
PA Corixa Corporation, Seattle, WA, UNITED STATES (U.S. corporation)  
PI US 2002131971 AI 20020919  
AI US 2001-33528 AI 20011226 (10)  
PRAI Continuation-in-part of Ser. No. US 2001-920300, filed on 31 Jul 2001,  
US 2001-302051P 20010629 (60)  
US 2001-279763P 20010328 (60)  
US 2000-221283P 20000803 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 8083  
INCL INCLM: 424/155.100  
INCLS: 536/023.200; 435/183.000; 435/069.100; 435/325.000; 435/320.100  
NCL INCLM: 424/155.100  
NCLS: 536/023.200; 435/183.000; 435/069.100; 435/325.000; 435/320.100  
IC [7]  
ICM: A61K039-395  
ICS: C07H021-04; C12N003-00; C12P021-02; C12N005-06  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 31 OF 76 USPTAFULL  
AN 2002:238649 USPTAFULL  
TI Methods for generating antigen-reactive T cells in vitro  
IN Srivastava, Pramod K., Avon, CT, United States  
PA University of Connecticut Health Center, Farmington, CT, United States  
(U.S. corporation)  
PI US 6451316 B1 20020917  
AI US 1998-166401 19981005 (9)  
DT Utility  
FS GRANTED  
LN.CNT 2357  
INCL INCLM: 424/193.100  
INCLS: 435/007.200; 435/007.210; 435/007.240; 435/325.000; 435/354.000;  
435/366.000; 435/355.000; 435/372.300; 435/373.000; 435/384.000;  
530/350.000  
NCL INCLM: 424/193.100  
NCLS: 435/007.200; 435/007.210; 435/007.240; 435/325.000; 435/354.000;  
435/366.000; 435/355.000; 435/372.300; 435/373.000; 435/384.000;

530/350.000  
IC [7]  
ICM: G01N033-53  
ICS: G01N033-567; C12N005-06; C12N005-08; A61K039-385  
530/350; 424/193.1; 435/7.2; 435/7.21; 435/7.24; 435/325; 435/354;  
435/355; 435/366; 435/372.3; 435/373; 435/384  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 32 OF 76 USPTAFULL  
AN 2002:238647 USPTAFULL  
TI MHC conjugates useful in ameliorating autoimmunity  
IN Clark, Brian R., Redwood City, CA, United States  
Sharma, Suresh D., Los Altos, CA, United States  
Lerch, Bernard L., Palo Alto, CA, United States  
PA Anergis, Inc., Seattle, WA, United States (U.S. corporation)  
PI US 6451314 B1 20020917  
AI US 2000-602807 20000623 (9)  
PRAI Continuation of Ser. No. US 1995-463351, filed on 5 Jun 1995, now  
patented, Pat. No. US 6106840 Division of Ser. No. US 1992-869293, filed  
on 14 Apr 1992, now patented, Pat. No. US 5468481 Continuation-in-part  
of Ser. No. US 1991-690840, filed on 23 Apr 1991, now patented, Pat. No.  
US 5260422 Continuation-in-part of Ser. No. US 1990-576084, filed on 30  
Aug 1990, now patented, Pat. No. US 5130297 Continuation of Ser. No. US  
1988-210594, filed on 23 Jun 1988, now abandoned  
DT Utility  
FS GRANTED  
LN.CNT 2474  
INCL INCLM: 424/185.100  
INCLS: 424/193.100  
NCL INCLM: 424/185.100  
NCLS: 424/193.100  
IC [7]  
ICM: A61K039-00  
EXF 530/403; 530/402; 530/868; 424/88; 424/185.1; 424/193.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 33 OF 76 USPTAFULL  
AN 2002:227950 USPTAFULL  
TI Human Wnt Gene  
IN Holloway, James L., Seattle, WA, UNITED STATES  
PI US 2002123103 AI 20020905  
AI US 2001-5947 AI 20011203 (10)  
PRAI Continuation of Ser. No. US 2000-715993, filed on 17 Nov 2000, PENDING  
DT Utility  
FS APPLICATION  
LN.CNT 3423  
INCL INCLM: 435/069.100  
INCLS: 435/007.200; 424/130.100; 536/023.500; 435/320.100; 435/325.000  
NCL INCLM: 435/069.100  
NCLS: 435/007.200; 424/130.100; 536/023.500; 435/320.100; 435/325.000  
IC [7]  
ICM: C12N005-02  
ICS: C12N015-74; C12N005-00; C12N015-70; C12N015-63; C12N015-00;  
C12N015-09; A61K039-395; C12P021-06; C07H021-04; G01N033-567; G01N033-53  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 34 OF 76 USPTAFULL  
AN 2002:227667 USPTAFULL  
TI Methods for isolation, quantification, characterization and modulation  
of antigen-specific T cells  
IN Albani, Salvatore, San Diego, CA, UNITED STATES  
PI US 2002122818 AI 20020905  
AI US 2001-756983 AI 20010109 (9)  
PRAI Continuation-in-part of Ser. No. US 1999-421506, filed on 19 Oct 1999,

PENDING Continuation-in-part of Ser. No. WO 1999-US24666, filed on 19

Oct 1999, UNKNOWN 19981020 (60)

PRAI US 1998-105018P

DT Utility

FS APPLICATION

LN.CNT 4793

INCL INCLM: 424/450.000

INCL INCLS: 424/261.100; 424/185.100

NCL NCLM: 424/450.000

IC NCLS: 424/261.100; 424/185.100

[7]

ICM: A61K039-00

ICS: A61K039-106; A61K009-127

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 35 OF 76 USPATFULL

AN 2002:221028 USPATFULL

TI Methods and compositions for protection against bovine viral diseases

IN Srikumaran, Subramaniam, Lincoln, NE, UNITED STATES

PA The Board of Regents of the University of Nebraska (2)

PI US 2002119163 A1 20020829

AI US 2001-3907 A1 20011102 (10)

PRAI US 2000-245970P 20001103 (60)

DT Utility

FS APPLICATION

LN.CNT 964

INCL INCLM: 424/186.100

NCL NCLM: 424/186.100

IC [7]

ICM: A61K039-12

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 36 OF 76 USPATFULL

AN 2002:213443 USPATFULL

TI AUTOREACTIVE PEPTIDES FROM HUMAN GLUTAMIC ACID-DECARBOXYLASE (GAD)

IN ENDL, JOSEF, WEILHEIM, GERMANY, FEDERAL REPUBLIC OF

STAHL, PETER, BERNBERG, GERMANY, FEDERAL REPUBLIC OF

ALBERT, WILFRIED, BERGFING, GERMANY, FEDERAL REPUBLIC OF

SCHENDEL, DOLORES, MUNCHEN, GERMANY, FEDERAL REPUBLIC OF

BOITARD, CHRISTIAN, PARIS, FRANCE

VAN ENDERT, PETER, PARIS, FRANCE

JUNG, GUNTHER-GERHARD, TUBINGEN, GERMANY, FEDERAL REPUBLIC OF

US 2002114816 A1 20020822

AI US 1998-981824 A1 19980918 (8)

WO 1996-EP3093 19960715

PRAI DE 1995-19525784 19950714

DT Utility

FS APPLICATION

LN.CNT 1382

INCL INCLM: 424/185.100

INCL INCLS: 514/013.000; 530/324.000

NCL NCLM: 424/185.100

IC NCLS: 514/013.000; 530/324.000

[7]

ICM: A61K038-00

ICS: A61K039-00; C07K017-00; C07K016-00; C07K007-00; C07K005-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 37 OF 76 USPATFULL

AN 2002:205879 USPATFULL

TI Human papilloma virus treatment

IN Nefse, John R., Devon, PA, UNITED STATES

Goldstone, Stephen E., New York, NY, UNITED STATES

Winnett, Mark T., Phoenixville, PA, UNITED STATES

Siegel, Marvin, Blue Bell, PA, UNITED STATES

Boux, Leslie J., Victoria, CANADA

PI US 2002110566 A1 20020815

AI US 2001-891823 A1 20010626 (9)

PRAI US 2000-214202P 20000626 (60)

DT Utility

FS APPLICATION

LN.CNT 1257

INCL INCLM: 424/204.100

NCL NCLM: 424/204.100

IC [7]

ICM: A61K039-12

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 38 OF 76 USPATFULL

AN 2002:191548 USPATFULL

TI Novel Fab fragment libraries and methods for their use

IN Hoozenboom, Hendricus Renerus Jacobus Mattheus, Maastricht, NETHERLANDS

PI US 2002102613 A1 20020801

AI US 2001-988899 A1 20011119 (9)

RLI Continuation of Ser. No. WO 2000-US13682, filed on 18 May 2000, UNKNOWN

PRAI EP 1999-201558 19990518

DT Utility

FS APPLICATION

LN.CNT 4310

INCL INCLM: 435/007.100

INCL INCLS: 435/320.100; 530/388.100; 435/069.100; 435/326.000; 536/023.530

NCL NCLM: 435/007.100

NCLS: 435/320.100; 530/388.100; 435/069.100; 435/326.000; 536/023.530

IC [7]

ICM: G01N033-53

ICS: C07H021-04; C12P021-02; C12N005-06; C07K016-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 39 OF 76 USPATFULL

AN 2002:191539 USPATFULL

TI Full-length human cDNAs encoding potentially secreted proteins

IN Milne Edwards, Jean-Baptiste Dumas, Paris, FRANCE

Bouqueleret, Lydie, Petit Lancy, SWITZERLAND

Jobert, Severin, Paris, FRANCE

US 2002102604 A1 20020801

AI US 2000-731872 A1 20001207 (9)

PRAI US 1999-169629P 19991208 (60)

US 2000-187470P 20000306 (60)

DT Utility

FS APPLICATION

LN.CNT 28061

INCL INCLM: 435/007.100

INCL INCLS: 536/023.100; 530/350.000

NCL NCLM: 435/007.100

NCLS: 536/023.100; 530/350.000

IC [7]

ICM: G01N033-53

ICS: C07H021-02; C07H021-04; C07K001-00; C07K014-00; C07K017-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 40 OF 76 USPATFULL

AN 2002:186246 USPATFULL

TI TPL-2/COT KINASE AND METHODS OF USE

IN ALLEN, HAMISH JOHN, BOYLSTON, MA, UNITED STATES

DIXON, RICHARD WOODWARD, NORTH GRAFTON, MA, UNITED STATES

KAMENS, JOANNE SARA, NEWTON CENTRE, MA, UNITED STATES

WICKRAMASINGHE, DINELI, NEWTON, MA, UNITED STATES

XU, YAJUN, WESTBOROUGH, MA, UNITED STATES

BELICH, MONICA POLIDORO, LONDON, UNITED KINGDOM

JOHNSTON, LELAND HERRIES, LONDON, UNITED KINGDOM

LEY, STEVEN CHARLES, HIGH BARNET, UNITED KINGDOM

PA SALMERON, ANDRES, LONDON, UNITED KINGDOM  
PI BASF AKTIEGESELLSCHAFT (U.S. corporation)  
AI US 2002099169 A1 20020725  
US 1999-374579 A1 19990813 (9)  
PRAI GB 1998-27712 19981216  
GB 1998-17930 19980818  
DT Utility  
FS APPLICATION  
LN.CNT 2998  
INCL INCLM: 530/324.000  
INCLS: 435/007.100; 530/350.000; 530/387.100; 514/002.000; 424/130.100  
NCLM: 530/324.000  
NCL INCLM: 435/007.100; 530/350.000; 530/387.100; 514/002.000; 424/130.100  
IC [7]  
ICM: A01N037-18  
ICS: A61K038-00; G01N033-53; A61K039-395; C07K005-00; C07K007-00;  
C07K016-00; C07K017-00; C07K001-00; C07K014-00  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 41 OF 76 USPATFULL  
AN 2002:185655 USPATFULL  
TI Zcys7: a member of the cystatin superfamily  
IN Presnell, Scott R., Tacoma, WA, UNITED STATES  
Gao, Zeren, Redmond, WA, UNITED STATES  
PI US 2002098568 A1 20020725  
US 2000-209668P 20000606 (60)  
AI US 2001-873134 A1 20010601 (9)  
PRAI US 2000-209668P 20000606 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3361  
INCL INCLM: 435/226.000  
INCLS: 435/320.100; 435/325.000; 536/023.200; 435/069.100  
NCLM: 435/226.000  
NCL INCLM: 435/320.100; 435/325.000; 536/023.200; 435/069.100  
IC [7]  
ICM: C12N009-64  
ICS: C07H021-04; C12P021-02; C12N005-06  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 42 OF 76 USPATFULL  
AN 2002:181548 USPATFULL  
TI Human serine protease  
IN Holloway, James L., Seattle, WA, United States  
PA ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)  
PI US 6423526 B1 20020723  
AI US 2000-715994 20001117 (9)  
PRAI US 1999-167083P 19991123 (60)  
DT Utility  
FS GRANTED  
LN.CNT 3354  
INCL INCLM: 435/219.000  
INCLS: 435/183.000; 435/212.000; 435/226.000; 435/252.300; 435/320.100;  
536/023.200  
NCLM: 435/219.000  
NCL INCLM: 435/183.000; 435/212.000; 435/226.000; 435/252.300; 435/320.100;  
536/023.200  
IC [7]  
ICM: C12N009-50  
EXF 435/183; 435/212; 435/219; 435/226; 435/252.3; 435/320.1; 536/23.2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 43 OF 76 USPATFULL  
AN 2002:172486 USPATFULL  
TI Dendritic cell co-stimulatory molecules

IN Pardoll, Drew M., Brookville, MD, UNITED STATES  
Tsuchiya, Haruo, Baltimore, MD, UNITED STATES  
Goraki, Kevin S., Baltimore, MD, UNITED STATES  
Teong, Su-Yi, Baltimore, MD, UNITED STATES  
PI US 2002091246 A1 20020711  
AI US 2001-794210 A1 20010228 (9)  
PRAI US 2000-200580P 20000428 (60)  
US 2000-240169P 20001013 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3534  
INCL INCLM: 536/023.200  
INCLS: 435/320.100; 435/372.000; 435/069.300; 435/069.700  
NCLM: 536/023.200  
NCL INCLM: 435/320.100; 435/372.000; 435/069.300; 435/069.700  
IC [7]  
ICM: C07H021-04  
ICS: C12P021-04; C12N005-08  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 44 OF 76 USPATFULL  
AN 2002:172479 USPATFULL  
TI Human chemokine  
IN Holloway, James L., Seattle, WA, UNITED STATES  
PI US 2002091239 A1 20020711  
AI US 2001-970108 A1 20011003 (9)  
PRAI US 2000-237777P 20001004 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3473  
INCL INCLM: 530/351.000  
INCLS: 435/069.500; 435/325.000; 435/320.100; 536/023.500; 435/252.300;  
435/410.000  
NCLM: 530/351.000  
NCL INCLM: 435/069.500; 435/325.000; 435/320.100; 536/023.500; 435/252.300;  
435/410.000  
IC [7]  
ICM: C07H014-52  
ICS: C07H021-04; C12P021-02; C12N005-06; C12N001-21; C12N005-04  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 45 OF 76 USPATFULL  
AN 2002:149127 USPATFULL  
TI Caveolin peptides and their use as therapeutics  
IN Sessa, William C., Madison, CT, UNITED STATES  
PI US 2002077283 A1 20020620  
AI US 2000-731023 A1 20001207 (9)  
PRAI US 2000-231327P 20000908 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2115  
INCL INCLM: 514/012.000  
INCLS: 435/184.000  
NCLM: 514/012.000  
NCL INCLM: 435/184.000  
IC [7]  
ICM: A61K038-17  
ICS: C12N009-99  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 46 OF 76 USPATFULL  
AN 2002:137157 USPATFULL  
TI Nucleic acid which encodes the tumor marker ZSIG62  
IN Sheppard, Paul O., Granite Falls, WA, United States  
Novak, Julia E., Bainbridge Island, WA, United States

PA Raymond, Fenella, Seattle, WA, United States  
 PI ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)  
 AI US 6403783 B1 20020611  
 US 2000-493565 20000118 (9)  
 PRAI US 1999-116321P 19990119 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 3540  
 INCL INCLM: 536/023.500  
 INCLS: 536/023.100; 435/320.100; 435/069.100; 435/325.000; 435/348.000;  
 435/349.000; 435/410.000; 435/254.100; 435/254.200  
 NCLM: 536/023.500  
 NCL 536/023.500  
 NCLS: 435/069.100; 435/254.100; 435/254.200; 435/320.100; 435/325.000;  
 435/348.000; 435/349.000; 435/410.000; 536/023.100  
 IC [7]  
 ICM: C07H021-04  
 ICS: C07H021-02; C12N015-00; C12N015-09; C12N015-63  
 536/23.5; 536/23.1; 435/320.1; 435/325; 435/69.1; 435/348; 435/349;  
 435/410; 435/243; 435/242.1; 435/254.1; 435/254.2  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 47 OF 76 USPATFULL  
 AN 2002:119336 USPATFULL  
 TI Immunotherapeutic stress protein-peptide complexes  
 IN against cancer  
 PA Srivastava, Pramod K., Avon, CT, UNITED STATES  
 PI Mount Sinai School of Medicine of New York University (U.S. corporation)  
 AI US 2002061316 A1 20020523  
 US 2001-992613 A1 20011114 (9)  
 RLI Continuation of Ser. No. US 2000-489218, filed on 21 Jan 2000, PENDING  
 Division of Ser. No. US 1998-61365, filed on 16 Apr 1998, PATENTED  
 Division of Ser. No. US 1994-315892, filed on 30 Sep 1994, PATENTED  
 DT Utility  
 FS APPLICATION  
 LN.CNT 811  
 INCL INCLM: 424/277.100  
 INCLS: 424/185.100  
 NCLM: 424/277.100  
 NCL 424/185.100  
 NCLS: 424/185.100  
 IC [7]  
 ICM: A61K039-00  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 48 OF 76 USPATFULL  
 AN 2002:95933 USPATFULL  
 TI Educational kit and method containing novel alpha helical protein-34  
 IN Conklin, Darrell C., Seattle, WA, United States  
 TAft, David W., Seattle, WA, United States  
 PA ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)  
 PI US 6380361 B1 20020430  
 AI US 2000-695458 20001024 (9)  
 PRAI US 1999-162623P 19991029 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 2860  
 INCL INCLM: 530/350.000  
 INCLS: 536/023.500; 435/006.000; 435/320.100  
 NCLM: 530/350.000  
 NCL 530/350.000  
 NCLS: 435/006.000; 435/320.100; 536/023.500  
 IC [7]  
 ICM: C12Q001-68  
 ICS: 530/350; 435/6; 435/320.1; 536/23.5  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 49 OF 76 USPATFULL

AN 2002:85168 USPATFULL  
 TI RECOMBINANT FUSION PROTEINS BASED ON RIBOSOME-INACTIVATING PROTEINS OF  
 THE MISTLETOE VISCUM ALBUM  
 IN ECK, JURGEN, HEPPENHEIM, GERMANY, FEDERAL REPUBLIC OF  
 SCHMIDT, ARNO, BUTTELBOHN, GERMANY, FEDERAL REPUBLIC OF  
 ZINKE, HOLGER, BICKENBACH, GERMANY, FEDERAL REPUBLIC OF  
 PI US 2002045208 A1 20020418  
 AI US 1999-347064 A1 19990702 (9)  
 RLI Continuation of Ser. No. WO 1998-EP9, filed on 2 Jan 1998, UNKNOWN  
 DT Utility  
 FS APPLICATION  
 LN.CNT 3070  
 INCL INCLM: 435/069.100  
 INCLS: 435/320.100; 435/252.330; 435/252.500; 435/253.500; 435/810.000;  
 536/023.400  
 NCLM: 435/069.100  
 NCL 435/069.100  
 NCLS: 435/320.100; 435/252.330; 435/252.500; 435/253.500; 435/810.000;  
 536/023.400  
 IC [7]  
 ICM: C12N015-74  
 ICS: C12N001-00; C12N015-70; C12N015-63; C12N015-09; C12N015-00;  
 C12N001-20; C12P021-06; C07H021-04  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 50 OF 76 USPATFULL  
 AN 2002:81671 USPATFULL  
 TI Methods for Producing B cells and antibodies from H2-O modified  
 IN transgenic mice  
 PA Karlsson, Lars, La Jolla, CA, United States  
 PI Leung, Wai-Ping, San Diego, CA, United States  
 AI Peterson, Per A., Rancho Santa Fe, CA, United States  
 Alfonso, Christopher, San Diego, CA, United States  
 Ortho McNeil Pharmaceutical, Inc., Raritan, NJ, United States (U.S.  
 corporation)  
 PI US 6372955 B1 20020416  
 AI US 2000-516390 20000301 (9)  
 RLI Continuation-in-part of Ser. No. US 1999-250898, filed on 16 Feb 1999,  
 now abandoned  
 PRAI US 1998-74847P 19980217 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 1242  
 INCL INCLM: 800/004.000  
 INCLS: 800/005.000; 800/006.000; 800/013.000; 800/014.000; 800/018.000  
 NCLM: 800/004.000  
 NCL 800/004.000  
 NCLS: 800/005.000; 800/006.000; 800/013.000; 800/014.000; 800/018.000  
 IC [7]  
 ICM: A01K067-00  
 ICS: A01K067-027; C12N015-00; C12P021-00  
 800/13; 800/14; 800/18; 800/4; 800/5; 800/6  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 51 OF 76 USPATFULL  
 AN 2002:66898 USPATFULL  
 TI New member of the lectin superfamily  
 IN Sheppard, Paul O., Granite Falls, WA, UNITED STATES  
 PI Bishop, Paul D., Fall City, WA, UNITED STATES  
 AI US 2002037551 A1 20020328  
 US 2001-801438 A1 20010307 (9)  
 PRAI US 2000-187918P 20000308 (60)  
 US 2000-233967P 20000920 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 3518  
 INCL INCLM: 435/069.100



INCLS: 435/006.000; 435/007.100; 536/023.500; 530/395.000  
 NCLM: 435/069.100  
 NCLS: 435/006.000; 435/007.100; 536/023.500; 530/395.000  
 IC [7]  
 ICM: C12Q001-68  
 ICS: G01N033-53; C07H021-04; C12P021-02; C07K014-435  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 52 OF 76 USPTAFULL  
 AN 2002:66639 USPTAFULL  
 TI Compositions comprising **heat shock proteins**  
 or alpha(2) macroglobulin, antigenic molecules and saponins, and methods  
 of use thereof  
 IN Armen, Garo H., Manhasset, NY, UNITED STATES  
 PI US 2002037290 A1 20020328  
 AI US 2001-909778 A1 20010720 (9)  
 PRAI US 2000-223133P 20000807 (60)  
 DT Utility  
 FS APPLICATION

LN.CNT 4136  
 INCL INCLM: 424/178.100  
 INCLS: 514/012.000; 514/026.000  
 NCL NCLM: 424/178.100  
 NCLS: 514/012.000; 514/026.000  
 IC [7]  
 ICM: A61K039-395  
 ICS: A61K038-17  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 53 OF 76 USPTAFULL  
 AN 2002:48016 USPTAFULL  
 TI Complexes of alpha (2) macroglobulin and antigenic molecules for  
 immunotherapy  
 IN Srivastava, Pramod K., Avon, CT, UNITED STATES  
 PI US 2002028207 A1 20020307  
 AI US 2001-873403 A1 20010504 (9)  
 RLI Continuation-in-part of Ser. No. US 2000-625139, filed on 25 Jul 2000,  
 PENDING  
 PRAI US 2000-209266P 20000602 (60)  
 DT Utility  
 FS APPLICATION

LN.CNT 4477  
 INCL INCLM: 424/185.100  
 INCLS: 424/190.100; 424/178.100; 530/391.100  
 NCL NCLM: 424/185.100  
 NCLS: 424/190.100; 424/178.100; 530/391.100  
 IC [7]  
 ICM: A61K039-40  
 ICS: A61K039-395; C07K016-46  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 54 OF 76 USPTAFULL  
 AN 2002:21834 USPTAFULL  
 TI Human cytokine receptor  
 IN Presnell, Scott R., Tacoma, WA, UNITED STATES  
 Xu, Wenfeng, Mukilteo, WA, UNITED STATES  
 Kindsvogel, Wayne, Seattle, WA, UNITED STATES  
 Chen, Zhi, Seattle, WA, UNITED STATES  
 PI US 200012669 A1 20020131  
 AI US 2000-728911 A1 20001201 (9)  
 PRAI US 1999-169049P 19991203 (60)  
 US 2000-232219P 20000913 (60)  
 US 2000-244610P 20001031 (60)  
 DT Utility  
 FS APPLICATION

LN.CNT 7478  
 INCL INCLM: 424/192.100  
 INCLS: 530/350.000; 536/023.500; 435/348.000; 435/326.000; 435/410.000;  
 435/252.100; 435/254.100; 435/255.100; 435/317.100; 435/069.100;  
 530/387.200; 530/388.100; 530/387.300; 530/389.100; 530/391.100;  
 514/012.000; 435/007.100; 435/006.000  
 NCL NCLM: 424/192.100  
 NCLS: 530/350.000; 536/023.500; 435/348.000; 435/326.000; 435/410.000;  
 435/252.100; 435/254.100; 435/255.100; 435/317.100; 435/069.100;  
 530/387.200; 530/388.100; 530/387.300; 530/389.100; 530/391.100;  
 514/012.000; 435/007.100; 435/006.000  
 IC [7]  
 ICM: A61K038-00  
 ICS: C12Q001-68; C07H021-04; A61K039-00; C12N001-20; C12N001-16;  
 C12N001-14; C12N001-12; C12P021-06; G01N033-53  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 55 OF 76 USPTAFULL  
 AN 2002:13790 USPTAFULL  
 TI Superantigen based methods and compositions for treatment of diseases  
 IN Terman, David Stephen, 3183 Palmero Way, Pebble Beach, CA, United States  
 93953  
 PI US 6340461 B1 20020122  
 AI US 1997-992877 19971217 (8)  
 PRAI US 1996-33172P 19961217 (60)  
 US 1997-44074P 19970417 (60)  
 DT Utility  
 FS GRANTED

LN.CNT 5893  
 INCL INCLM: 424/193.100  
 INCLS: 424/192.100; 424/194.100; 424/277.100; 424/278.100; 424/280.100;  
 424/282.100; 435/068.100; 435/069.100; 435/069.300; 435/069.700  
 NCL NCLM: 424/193.100  
 NCLS: 424/192.100; 424/194.100; 424/277.100; 424/278.100; 424/280.100;  
 424/282.100; 435/068.100; 435/069.100; 435/069.300; 435/069.700  
 IC [7]  
 ICM: A61K039-385  
 ICS: A61K039-00; A61K039-39; A61K045-00; C12N015-09; C12N015-12;  
 C12N015-62; C12N015-63  
 EXF 424/277.1; 424/193.1; 424/194.1; 424/192.1; 424/278.1; 424/280.1;  
 424/282.1; 435/68.1; 435/69.7; 435/69.3; 435/69.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 56 OF 76 USPTAFULL  
 AN 2002:9741 USPTAFULL  
 TI Method for identifying cytotoxic T-cell epitopes  
 IN Nicolette, Charles A., Mariborough, MA, United States  
 PA Genzyme Corporation, Framingham, MA, United States (U.S. corporation)  
 PI US 6338945 B1 20020115  
 AI US 1997-989195 19971211 (8)  
 RLI Continuation of Ser. No. WO 1997-US4479, filed on 20 Mar 1997  
 PRAI US 1996-13706P 19960320 (60)  
 DT Utility  
 FS GRANTED

LN.CNT 1648  
 INCL INCLM: 435/007.100  
 INCLS: 435/004.000; 435/DIG.001; 435/DIG.015; 435/DIG.035; 530/300.000;  
 530/328.000; 436/518.000  
 NCL NCLM: 435/007.100  
 NCLS: 435/004.000; 435/DIG.001; 435/DIG.015; 435/DIG.035; 436/518.000;  
 530/300.000; 530/328.000  
 IC [7]  
 ICM: G01N033-53  
 ICS: G01N033-543; A61K038-00  
 530/300; 530/327; 530/328; 530/333; 530/334; 530/335; 436/518; 436/501;  
 EXF

435/524; 435/7.1; 435/DIG.1; 435/DIG.2; 435/DIG.14; 435/DIG.15;  
435/DIG.22; 435/DIG.34; 435/DIG.35; 435/DIG.21  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 57 OF 76 USPTFULL  
AN 2002.3610 USPTFULL  
TI Zecel: a human metalloenzyme  
IN Sheppard, Paul O., Granite Falls, WA, UNITED STATES  
PI US 2002001583 AI 20020103  
AI US 2001-846996 AI 20010501 (9)  
RLI Division of Ser. NO. US 1999-440325, filed on 15 Nov 1999, PENDING  
PRAI US 1998-109783P 19981125 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3929  
INCL INCLM: 424/094.630  
INCL INCLM: 424/094.670; 435/007.400; 435/226.000; 530/388.260  
NCL NCLM: 424/094.630  
NCLM: 424/094.670; 435/007.400; 435/226.000; 530/388.260  
IC [7]  
ICM: A61K038-48  
ICS: GOIN033-573; C12N009-64  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 58 OF 76 USPTFULL  
AN 2001.231135 USPTFULL  
TI Immune response enhancer  
IN Malkovsky, Miroslav, Madison, WI, United States  
PA Wisconsin Alumni Research Foundation, Madison, WI, United States (U.S. corporation)  
PI US 6331388 B1 20011218  
AI US 1997-955565 19971017 (8)  
DT Utility  
FS GRANTED  
LN.CNT 2526  
INCL INCLM: 435/005.000  
INCL INCLM: 424/278.100; 435/007.210; 435/007.220; 435/007.230; 435/007.240;  
435/007.310; 435/007.320; 435/069.100; 435/375.000; 514/044.000  
NCL NCLM: 435/005.000  
NCLM: 424/278.100; 435/007.210; 435/007.220; 435/007.230; 435/007.240;  
435/007.310; 435/007.320; 435/069.100; 435/375.000; 514/044.000  
IC [7]  
ICM: A61K031-7088  
ICS: C12N005-00; GOIN033-569  
EXF 435/5; 435/7.21; 435/7.22; 435/7.23; 435/7.24; 435/7.31; 435/7.32;  
435/69.1; 435/375; 424/278.1; 514/44  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 59 OF 76 USPTFULL  
AN 2001.226441 USPTFULL  
TI Interferon-epsilon.  
IN Konklin, Darrell C., Seattle, WA, United States  
Grant, Francis J., Seattle, WA, United States  
Rixon, Mark W., Issaquah, WA, United States  
Kindsvogel, Wayne, Seattle, WA, United States  
ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)  
PI US 6329175 B1 20011211  
AI US 1999-397992 19990916 (9)  
DT Utility  
FS GRANTED  
LN.CNT 4876  
INCL INCLM: 435/069.510  
INCL INCLM: 536/023.520; 435/325.000; 435/348.000; 435/349.000; 435/410.000;  
435/252.300; 435/254.100; 435/255.100; 435/320.100; 530/351.000

NCL NCLM: 435/069.510  
NCLM: 435/252.300; 435/254.100; 435/255.100; 435/320.100; 435/325.000;  
435/348.000; 435/349.000; 435/410.000; 530/351.000; 536/023.520  
IC [7]  
ICM: C07H021-04  
ICS: C12N005-00; C12N001-20; C12N001-15  
EXF 435/69.51; 435/325; 435/348; 435/349; 435/410; 435/252.3; 435/254.1;  
435/253.1; 435/320.1; 536/23.52; 530/351  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 60 OF 76 USPTFULL  
AN 2001.224217 USPTFULL  
TI Human ribonuclease  
IN Konklin, Darrell C., Seattle, WA, United States  
PI US 2001049434 AI 20011206  
AI US 2001-801231 AI 20010307 (9)  
PRAI US 2000-187917P 20000308 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3760  
INCL INCLM: 536/023.100  
NCL NCLM: 536/023.100  
IC [7]  
ICM: C07H021-02  
ICS: C07H021-04  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 61 OF 76 USPTFULL  
AN 2001.196827 USPTFULL  
TI Murine interferon-alpha.  
IN Presnell, Scott R., Tacoma, WA, United States  
Feldhaus, Andrew L., Lynnwood, WA, United States  
Gao, Zeren, Redmond, WA, United States  
ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)  
PI US 6312924 B1 20011106  
AI US 2000-528760 20000317 (9)  
DT Utility  
FS GRANTED  
LN.CNT 4309  
INCL INCLM: 435/069.510  
INCL INCLM: 435/320.100; 435/325.000; 435/070.500; 435/252.800; 435/254.110;  
435/348.000; 435/349.000; 435/419.000; 536/023.520; 536/023.100;  
514/002.000; 530/351.000  
NCL NCLM: 435/069.510  
NCLM: 435/070.500; 435/252.800; 435/254.110; 435/320.100; 435/325.000;  
435/348.000; 435/349.000; 435/419.000; 514/002.000; 530/351.000;  
536/023.100; 536/023.520  
IC [7]  
ICM: C12P021-04  
ICS: C12N015-09; C12N015-63; C12N001-20  
EXF 435/69.51; 435/320.1; 435/325; 435/70.5; 435/252.3; 435/254.11; 435/348;  
435/349; 435/419; 530/351; 536/23.52; 536/23.1; 514/2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 62 OF 76 USPTFULL  
AN 2001.194129 USPTFULL  
TI Educational kit and method using tumor necrosis factor-stimulated gene and protein  
IN Holloway, James L., Seattle, WA, United States  
PI US 2001036643 AI 20011101  
AI US 2000-728912 AI 20001201 (9)  
PRAI US 1999-169252P 19991206 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3592

INCL INCLM: 435/007.920  
INCL: 530/351.000; 530/388.230; 536/023.500  
NCL NCLM: 435/007.920  
NCL: 530/351.000; 530/388.230; 536/023.500  
IC [7]  
ICM: G01N033-53  
ICS: G01N033-537; C07H021-04; C07K014-52; C07K016-24  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 63 OF 76 USPTAFULL  
AN 2001:142135 USPTAFULL  
TI Zacc 1: a human metalloenzyme  
IN Sheppard, Paul O., Granite Falls, WA, United States  
PA ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)  
PI US 6280994 B1 20010828  
AI US 1999-440325 19991115 (9)  
DT Utility  
FS GRANTED  
LN.CNT 3706  
INCL INCLM: 435/226.000  
INCL: 435/069.100; 435/069.700; 435/252.300; 435/320.100;  
536/023.200; 536/023.400  
NCL NCLM: 435/226.000  
NCL: 435/069.100; 435/069.700; 435/252.300; 435/320.100;  
536/023.200; 536/023.400  
IC [7]  
ICM: C12N015-57  
ICS: C12N009-64; C12N015-74; C12N015-82; C12N015-85  
EXF 435/69.1; 435/69.7; 435/226; 435/252.3; 435/320.1; 536/23.2;  
536/23.4  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 64 OF 76 USPTAFULL  
AN 2000:134754 USPTAFULL  
TI Methods for generating cytotoxic T cells in vitro  
IN Srivastava, Pramod K., Riverdale, NY, United States  
Blinder, Robert, Bronx, NY, United States  
Blachere, Nathalie E., Bronx, NY, United States  
Fordham University, Bronx, NY, United States (U.S. corporation)  
PA US 6130087 20001010  
AI US 1996-726967 19961007 (8)  
DT Utility  
FS GRANTED  
LN.CNT 1534  
INCL INCLM: 435/372.300  
INCL: 435/375.000; 435/377.000  
NCL NCLM: 435/372.300  
NCL: 435/375.000; 435/377.000  
IC [7]  
ICM: C12N005-06  
ICS: C12N005-08  
EXF 435/372.3; 435/377; 435/375  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 65 OF 76 USPTAFULL  
AN 2000:109346 USPTAFULL  
TI MHC conjugates useful in ameliorating autoimmunity  
IN Clark, Brian R., Redwood City, CA, United States  
Sharma, Somen D., Los Altos, CA, United States  
Lerch, Bernard L., Palo Alto, CA, United States  
Anergen, Inc., Redwood City, CA, United States (U.S. corporation)  
PA US 6106840 20000822  
PI US 1995-462351 19950605 (8)  
AI Division of Ser. No. US 1992-869293, filed on 14 Apr 1992, now patented,  
Pat. No. US 5468481 which is a continuation-in-part of Ser. No. US

1991-690840, filed on 23 Apr 1991, now patented, Pat. No. US 5260422  
which is a continuation-in-part of Ser. No. US 1990-576084, filed on 30  
Aug 1990, now patented, Pat. No. US 5130297 which is a continuation of  
Ser. No. US 1988-210594, filed on 23 Jun 1988, now abandoned

DT Utility  
FS GRANTED  
LN.CNT 2490  
INCL INCLM: 424/195.110  
INCL: 424/185.100; 530/300.000; 530/350.000; 530/395.000; 530/403.000;  
530/868.000  
NCL NCLM: 424/195.110  
NCL: 424/185.100; 530/300.000; 530/350.000; 530/395.000; 530/403.000;  
530/868.000  
IC [7]  
ICM: A61K039-00  
ICS: A61K039-385; C07K014-435; C07K014-705  
EXF 530/300; 530/350; 530/395; 530/403; 530/868; 424/185.1; 424/195.11  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 66 OF 76 USPTAFULL  
AN 2000:91742 USPTAFULL  
TI Prokaryotic expression of MHC proteins  
IN Rhodes, Eric T., Vallejo, CA, United States  
Nag, Bishwajit, Fremont, CA, United States  
Corixa Corporation, Seattle, WA, United States (U.S. corporation)  
PA US 6090587 20000718  
PI US 1995-470535 19950606 (8)  
AI Division of Ser. No. US 1994-329010, filed on 25 Oct 1994 which is a  
continuation-in-part of Ser. No. US 1993-143575, filed on 25 Oct 1993,  
now abandoned  
DT Utility  
FS GRANTED  
LN.CNT 2067  
INCL INCLM: 435/069.300  
INCL: 435/069.100; 435/252.300; 435/252.330; 435/320.100; 530/300.000;  
530/402.000  
NCL NCLM: 435/069.300  
NCL: 435/069.100; 435/252.300; 435/252.330; 435/320.100; 530/300.000;  
530/402.000  
IC [7]  
ICM: C12P021-06  
ICS: C12N001-21; C12N015-12; C12N015-63  
EXF 435/69.3; 435/252; 435/252.33; 435/69.1; 435/320.1; 530/300; 530/350;  
530/402  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 67 OF 76 USPTAFULL  
AN 2000:57603 USPTAFULL  
TI Immune mediators and related methods  
IN Kindsvogel, Wayne, Seattle, WA, United States  
Reich, Eva Pia, Palo Alto, CA, United States  
Gross, Jane A., Seattle, WA, United States  
Anergen, Inc., Redwood City, CA, United States (U.S. corporation)  
PA US 6060309 20000509  
PI US 1997-855925 19970514 (8)  
AI Continuation of Ser. No. US 1995-483241, filed on 7 Jun 1995, now  
abandoned  
DT Utility  
FS GRANTED  
LN.CNT 1363  
INCL INCLM: 435/325.000  
INCL: 530/350.000; 530/387.100; 530/388.200; 530/388.220; 530/388.750;  
530/389.600; 530/391.100  
NCL NCLM: 435/325.000  
NCL: 530/350.000; 530/387.100; 530/388.200; 530/388.220; 530/388.750;

IC [7] 530/389.600; 530/391.100  
 ICM: C12N005-06  
 ICS: C07K016-28; C07K017-14  
 EXF 435/325; 530/387.1; 530/388.2; 530/388.22; 530/388.75; 530/389.6;  
 530/391.1; 530/350  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 68 OF 76 USPATFULL  
 AN 2000:31209 USPATFULL  
 TI Methods for making HLA binding peptides and their uses  
 IN Kubo, Ralph T., San Diego, CA, United States  
 Grey, Howard M., La Jolla, CA, United States  
 Sette, Alessandro, La Jolla, CA, United States  
 Celis, Esteban, San Diego, CA, United States  
 PA Epimmune Inc., San Diego, CA, United States (U.S. corporation)  
 PI US 6037135 20000314  
 AI US 1993-159339 19931129 (8)  
 RLI Continuation-in-part of Ser. No. US 1993-103396, filed on 6 Aug 1993,  
 now abandoned which is a continuation-in-part of Ser. No. US 1993-27746,  
 filed on 5 Mar 1993, now abandoned which is a continuation-in-part of  
 Ser. No. US 1992-926666, filed on 7 Aug 1992, now abandoned

DT Utility  
 FS Granted  
 IN.CNT 13053  
 INCL INCLM: 435/007.240  
 INCLS: 435/007.100; 435/007.200; 530/328.000; 424/185.100  
 NCL NCLM: 435/007.240  
 NCLS: 424/185.100; 435/007.100; 435/007.200; 530/328.000  
 IC [7]  
 ICM: C12Q001-00  
 ICS: C12Q021-00  
 EXF 424/88; 424/184.1; 424/185.1; 514/2; 514/14-16; 530/300; 530/326-329;  
 530/868; 530/338; 435/7.1; 435/7.2; 435/7.24  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 69 OF 76 USPATFULL  
 AN 1999:170214 USPATFULL  
 TI Purification and characterization of MHC-peptide  
 IN complexes useful in ameliorating autoimmunity  
 PA Nag, Bishwajit, Pacifica, CA, United States  
 PI Anerg, Inc., Redwood City, CA, United States (U.S. corporation)  
 AI US 6007820 19991228  
 RLI Division of Ser. No. US 1994-227372, filed on 14 Apr 1994, now patented,  
 Pat. No. US 5763585 which is a continuation-in-part of Ser. No. US  
 1993-136216, filed on 13 Oct 1993, now abandoned

DT Utility  
 FS Granted  
 IN.CNT 1849  
 INCL INCLM: 424/193.100  
 INCLS: 530/412.000; 530/413.000  
 NCL NCLM: 424/193.100  
 NCLS: 530/412.000; 530/413.000  
 IC [6]  
 ICM: A61K039-385  
 EXF 530/412; 530/413; 424/193.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 70 OF 76 USPATFULL  
 AN 1999:120883 USPATFULL  
 TI Stress protein-peptide complexes as prophylactic and  
 IN therapeutic vaccines against intracellular pathogens  
 PA Srivastava, Pramod K., Riverdale, NY, United States  
 Mount Sinai School of Medicine of the City University of New York, New

York, NY, United States (U.S. corporation)  
 PI US 5961979 19991005  
 AI US 1994-210421 19940316 (8)  
 DT Utility  
 FS Granted  
 IN.CNT 2491  
 INCL INCLM: 424/193.100  
 INCLS: 424/190.100; 424/191.100; 424/192.100; 424/196.110; 424/197.110;  
 514/002.000; 514/021.000; 530/412.000  
 NCL NCLM: 424/193.100  
 NCLS: 424/190.100; 424/191.100; 424/192.100; 424/196.110; 424/197.110;  
 514/002.000; 514/021.000; 530/412.000  
 IC [6]  
 ICM: A61K039-02  
 ICS: A61K039-12; A61K039-385  
 EXF 514/2; 514/21; 424/193.1; 424/185.1; 424/190.1; 424/191.1; 424/192.1;  
 424/196.11; 424/197.11; 530/412  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 71 OF 76 USPATFULL  
 AN 1998:130961 USPATFULL  
 TI Photoreactive peptide derivatives  
 IN Luescher, Immanuel, Epalinges, Switzerland  
 Anjuere, Fabienne, Epalinges, Switzerland  
 Layer, Andreas, Epalinges, Switzerland  
 Romero, Pedro, Epalinges, Switzerland  
 PA Cerottini, Jean-Charles, Epalinges, Switzerland  
 Ludwig Institute for Cancer Research, New York, NY, United States (U.S.  
 corporation)  
 PI US 5827073 19981027  
 AI US 1995-498461 19950705 (8)  
 DT Utility  
 FS Granted  
 IN.CNT 830  
 INCL INCLM: 435/007.240  
 INCLS: 435/068.100; 435/196.000; 436/501.000; 436/545.000; 530/345.000  
 NCL NCLM: 435/007.240  
 NCLS: 435/068.100; 435/196.000; 436/501.000; 436/545.000; 530/345.000  
 IC [6]  
 ICM: C07K001-13  
 ICS: G01N033-534; G01N033-566  
 EXF 435/7.24; 435/68.1; 436/501; 436/545; 530/345; 535/196  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 72 OF 76 USPATFULL  
 AN 1998:65363 USPATFULL  
 TI Method of making MHC-peptide complexes using metal  
 IN chelate affinity chromatography  
 PA Nag, Bishwajit, Pacifica, CA, United States  
 PI Anerg, Inc., Redwood City, CA, United States (U.S. corporation)  
 AI US 5763585 19980609  
 RLI Continuation-in-part of Ser. No. US 1993-136216, filed on 13 Oct 1993,  
 now abandoned  
 DT Utility  
 FS Granted  
 IN.CNT 1761  
 INCL INCLM: 530/413.000  
 INCLS: 530/412.000; 530/415.000  
 NCL NCLM: 530/413.000  
 NCLS: 530/412.000; 530/415.000  
 IC [6]  
 ICM: C07K001-22  
 EXF 530/412; 530/413; 530/415  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 73 OF 76 USPATFULL  
AN 1998:34041 USPATFULL  
TI MHC class II beta chain/peptide complexes useful in ameliorating deleterious immune responses  
IN Nag, Bishwajit, Pacifica, CA, United States  
Clark, Brian R., Redwood City, CA, United States  
Sharma, Suresh D., Los Altos, CA, United States  
McConnell, Harden, Stanford, CA, United States  
PA Amergen Inc., Redwood City, CA, United States (U.S. corporation)  
PI US 5734023 19980331  
AI US 1995-483021 19950607 (8)  
RLI Division of Ser. No. US 1995-397533, filed on 2 Mar 1995, now abandoned  
which is a continuation of Ser. No. US 1994-208072, filed on 3 Mar 1994,  
now abandoned which is a continuation of Ser. No. US 1992-978946, filed  
on 18 Nov 1992, now abandoned which is a continuation-in-part of Ser.  
No. US 1991-793938, filed on 19 Nov 1991, now abandoned

DT Utility  
FS Granted  
LN.CNT 2198  
INCL INCLM: 530/403.000  
INCLS: 424/185.100; 424/193.100; 530/300.000; 530/395.000; 530/402.000;  
530/868.000  
NCL NCLM: 530/403.000  
NCLS: 424/185.100; 424/193.100; 530/300.000; 530/395.000; 530/402.000;  
530/868.000  
IC [6]  
ICM: C07K014-74  
ICS: C07K017-00; A61K039-385  
EXP 530/300; 530/350; 530/395; 530/403; 530/868; 530/402; 424/184.1;  
424/185.1; 424/193.1; 444/195.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 74 OF 76 USPATFULL  
AN 95:103247 USPATFULL  
TI MHC class II-peptide conjugates useful in ameliorating autoimmunity  
IN Sharma, Suresh D., Los Altos, CA, United States  
Clark, Brian R., Redwood City, CA, United States  
Lerch, Bernard L., Palo Alto, CA, United States  
PA Amergen, Inc., Redwood City, CA, United States (U.S. corporation)  
PI US 5468481 19951121  
AI US 1992-86293 19920414 (7)  
RLI Continuation-in-part of Ser. No. US 1991-690840, filed on 23 Apr 1991,  
now patented, Pat. No. US 5260422 which is a continuation-in-part of  
Ser. No. US 1990-576084, filed on 30 Aug 1990, now patented, Pat. No. US  
5130297 which is a continuation of Ser. No. US 1988-210594, filed on 23  
Jun 1988, now abandoned And a continuation-in-part of Ser. No. US  
1990-635840, filed on 28 Dec 1990, now patented, Pat. No. US 5284935  
which is a continuation-in-part of Ser. No. US 1989-367751, filed on 21  
Jun 1989, now patented, Pat. No. US 5194425

DT Utility  
FS Granted  
LN.CNT 2266  
INCL INCLM: 424/125.100  
INCLS: 530/395.000; 530/402.000; 530/403.000; 530/868.000; 514/002.000;  
514/008.000; 424/184.100; 424/193.100; 424/278.100  
NCL NCLM: 424/185.100  
NCLS: 424/184.100; 424/193.100; 424/278.100; 514/002.000; 514/008.000;  
530/395.000; 530/402.000; 530/403.000; 530/868.000  
IC [6]  
ICM: A61K039-385  
ICS: C07K014-74  
EXP 514/2; 514/8; 514/12; 424/88; 424/184.1; 424/193.1; 424/194.1-197.11;  
530/395; 530/403; 530/868  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 75 OF 76 USPATFULL  
AN 94:11502 USPATFULL  
TI MHC-mediated toxic conjugates useful in ameliorating autoimmunity  
IN Clark, Brian R., Redwood City, CA, United States  
Sharma, Suresh D., Los Altos, CA, United States  
Lerch, L. Bernard, Menlo Park, CA, United States  
PA Amergen, Inc., Redwood City, CA, United States (U.S. corporation)  
PI US 5284935 19940208  
AI US 1990-635840 19901228 (7)  
RLI Continuation-in-part of Ser. No. US 1990-576084, filed on 30 Aug 1990,  
now patented, Pat. No. US 5130297 which is a continuation of Ser. No. US  
1988-210594, filed on 23 Jun 1988, now abandoned And a  
continuation-in-part of Ser. No. US 1989-367751, filed on 21 Jun 1989,  
now patented, Pat. No. US 5194425

DT Utility  
FS Granted  
LN.CNT 1708  
INCL INCLM: 530/403.000  
INCLS: 530/395.000; 530/806.000; 530/807.000; 530/868.000; 424/088.000  
NCL NCLM: 424/185.100  
NCLS: 424/193.100; 424/810.000; 530/395.000; 530/403.000; 530/806.000;  
530/807.000; 530/868.000  
IC [5]  
ICM: C07K001-10  
ICS: C07K001-14; C07K001-04  
EXP 530/300; 530/395; 530/402; 530/403; 530/806; 530/807; 530/868; 530/412;  
530/413; 530/414; 514/2; 514/8; 424/88  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 76 OF 76 USPATFULL  
AN 93:20521 USPATFULL  
TI MHC-mediated toxic conjugates useful in ameliorating autoimmunity  
IN Sharma, Suresh D., Los Altos, CA, United States  
Lerch, L. Bernard, Menlo Park, CA, United States  
Clark, Brian R., Redwood City, CA, United States  
PA Amergen, Inc., Redwood City, CA, United States (U.S. corporation)  
PI US 5194425 19930316  
AI US 1989-367751 19890621 (7)  
RLI Continuation-in-part of Ser. No. US 1988-210594, filed on 23 Jun 1988  
DT Utility  
FS Granted  
LN.CNT 1401  
INCL INCLM: 514/008.000  
INCLS: 530/402.000; 530/403.000; 530/395.000; 514/903.000; 424/088.000  
NCL NCLM: 424/193.100  
NCLS: 424/185.100; 514/008.000; 514/903.000; 530/395.000; 530/402.000;  
530/403.000  
IC [5]  
ICM: A61K037-02  
ICS: A61K035-28  
EXP 530/402; 530/403; 530/807; 530/829; 424/88  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>  
---Logging off of STN---  
=>  
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
242.35	242.56

STN INTERNATIONAL LOGOFF AT 16:33:37 ON 17 OCT 2002